

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Depression and associated factors among HIV-positive smokers receiving care at HIV outpatient clinics in Vietnam

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-077015
Article Type:	Original research
Date Submitted by the Author:	23-Jun-2023
Complete List of Authors:	Nguyen, Nam; Institute of Social and Medical Studies Nguyen, Trang; Institute of Social and Medical Studies Vu, Giap; Bach Mai Hospital Truong, Nga; Institute of Social and Medical Studies Pham, Yen; Institute of Social and Medical Studies Guevara Alvarez, Gloria; New York University Armstrong-Hough, Mari ; New York University R Shelley, Donna; New York University
Keywords:	Depression & mood disorders < PSYCHIATRY, HIV & AIDS < INFECTIOUS DISEASES, MENTAL HEALTH, PUBLIC HEALTH

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

## Depression and associated factors among HIV-positive smokers receiving care at HIV outpatient clinics in Vietnam

Nam Truong Nguyen<sup>1</sup>, Trang Nguyen<sup>1</sup>, Giap Van Vu<sup>3</sup>, Nga Truong<sup>1</sup>, Yen Pham<sup>1</sup>, Gloria Guevara Alvarez<sup>2</sup>, Mari Armstrong-Hough<sup>2</sup>, Donna Shelley<sup>2</sup>

<sup>1</sup>Institute of Social and Medical Studies, 19, Alley 6, Dong Bat Street, My Dinh 2 Ward, South Tu Liem District, Ha Noi, Vietnam

<sup>2</sup>School of Global Public Health, New York University, 708 Broadway, New York, NY, USA

<sup>3</sup>Bach Mai Hospital, 78 Giai Phong Road, Ha Noi, Vietnam

### Corresponding author

Nam Truong Nguyen

[ntnam@isms.org.vn](mailto:ntnam@isms.org.vn)

### Abstract

#### Purpose

Assess the prevalence of depressive symptoms and associated factors among people living with HIV (PLWH) who are current smokers receiving treatment at HIV outpatient clinics (OPCs) in Ha Noi, Vietnam.

#### Method

We analyzed data from a cross sectional survey conducted from 12/2022 to 5/2023 with 527 smokers receiving HIV treatment at HIV outpatient clinics. The Center for Epidemiology Scale for Depression (CES-D 8) was used to assess depressive symptoms. Bivariate and multiple logistic regression analyses were used to assess the association between depressive symptoms, tobacco dependence, and other characteristics.

#### Results

The prevalence of depressive symptoms among smokers living with HIV was 38.3%. HIV-positive smokers who had a higher level of tobacco dependence (OR =1.09, 95% CI 1.01-1.19), and reported health as fair/poor (OR =2.39, 95% CI 1.48-3.86) were more likely to have depression symptoms compared with HIV-positive smokers who had a lower level of tobacco dependence, and self-reported their health as good/very good/excellent. HIV-positive smokers who were married were less likely to have depression symptoms compared with HIV-positive smokers who were not married (OR=0.28 95% CI 0.17-0.46).

#### Conclusion

Prevalence of depressive symptoms among smokers receiving HIV care at OPCs was high. Both depression and tobacco use screening and treatment should be included as part of ongoing care treatment plans at HIV OPCs.

**Keywords:** Depression; depressive symptoms; tobacco use; HIV; people living with HIV; Vietnam; low-and middle-income country.

## Strengths and limitations of this study

This is one of the first studies to examine depression and associated factors among smokers living with HIV in Vietnam. The findings make it imperative to support HIV treatment settings to integrate screening for both tobacco use and depression into routine care.

The study used a CES-D 8, a validated scale to screen depressive symptoms with a large sample of smokers living with HIV and receiving treatment and care at a large number of HIV outpatient clinics.

The cross-sectional design does not allow for conclusions about the direction of the associations between depression and other factors.

Participants were drawn from a sample of PLWH who were receiving treatment at HIV OPCs. This may therefore not represent the larger population of PLWH in Viet Nam.

The CES-D 8 is a screening tool rather than a diagnostic instrument, this study could only assess the prevalence of depressive symptoms among PLWH instead of the prevalence of diagnosed depression.

## Introduction

HIV infection remains a major public health issue, with over 38 million people living with HIV (PLWH) globally [1]. With increased access to antiretroviral medication the HIV infection has become a manageable chronic health condition, with a lifespan comparable to that of general population [2, 3]. However, gains in life expectancy are threatened by the growing burden of noncommunicable diseases (NCDs) among PLWH [4]. This is in part due to high rates of tobacco use in this population, particularly in LMIC countries like Viet Nam where smoking prevalence among male PLWH is over 50% [4, 5]. PLWH who use tobacco are at increased risk of HIV and non-HIV related chronic diseases including cancer and cardiovascular disease compared to PLWH who do not smoke [6].

PLWH experience other risk factors for poor health including higher rates of depression compared with the general population [7-9]. Prevalence estimates for depression among PLWH range widely from 25.6% to 56.7% [6, 10-15]. Studies conducted in Viet Nam show a similarly high prevalence of depression among PLWH, ranging from 18.7% to 44% [16-21].

Depression is common among smokers, particularly among smokers living with HIV [22, 23]. The high co-occurrence of smoking and depression in this population is a major public health concern. Depression can compromise smoking cessation, negatively impacts adherence to ART, and is associated with faster progression of disease and greater risk of other health risk behaviors, including alcohol abuse and drug use and poorer health outcomes [22, 24-29].

Despite the deleterious effects of the co-occurrence of depression and tobacco use on health outcomes among PLWH, there is a lack of data on correlates of depression in this population. To begin to fill this gap in research, we conducted a cross sectional analysis of factors associated with depression among PLWH who smoke and are receiving treatment in HIV outpatient clinics in Ha Noi, Vietnam.

## Methods

### *Study design*

We conducted a cross sectional analysis of data obtained from a quantitative survey of 527 smokers living with HIV. Data were collected between 12/2022 and 5/2023. The sample is a subset of participants taking part in a randomized controlled trial that is comparing the effectiveness of three smoking cessation interventions delivered in 13 HIV OPCs in Ha Noi, Vietnam. Participants were screened for tobacco use at the time of registration for a routine visit. Participants were eligible to enroll if they were 18 years of age or over, an active patient at the OPCs, a current cigarette only or dual user (waterpipe and cigarettes), had a mobile phone, and lived in Ha Noi.

The survey was administered in person using a structured questionnaire in Vietnamese. Signed informed consent was obtained from all respondents. The institutional review boards of the Institute of Social Medical Studies and the New York University School of Medicine approved this research.

## ***Measures***

### *Dependent variable*

The 8-item Center for Epidemiology Scale for Depression (CES-D 8) was used to assess depression symptoms[30]. Respondents were asked to rate how much of the time during the past week they experienced the following behaviors or feelings: (1) “I felt depressed”; (2) “I felt everything I did was an effort”; (3) “My sleep was restless”; (4) “I were happy”; (5) “I felt lonely”; (6) “I enjoyed life”; (7) “I felt sad”; (8) “I could not get going”. Responses were coded as 0=Rarely or none of the time (less than 1 day); 1= Some or a little of the time (1-2 days); 2= Occasionally or a moderate amount of time (3-4 days); 3= Most or all of the time (5-7 days). These responses resulted in scores ranging from 0 to 24. A score of  $\geq 9$  identifies people with clinically significant depressive symptoms[31].

### *Independent variables*

Health status was measured using a self-rated health question asking respondents to assess their health status including 1 = Poor, 2=Fair, 3 = Good, 4 = Very Good, 5 = “Excellent [32].

Social support was assessed using the Multidimensional Scale of Perceived Social Support Scale (MPSS)[33], which aggregates three types of social support significant other, family and friends. Respondents were asked to rate 12 social support statements. Responses ranged from 1 “Strongly disagree” to 4 “Strongly agree”. Mean scores were calculated for each of the three social support categories.

Tobacco dependence was assessed using the Fagerstrom Test for Nicotine Dependence which includes six items that evaluate the quantity of cigarette consumption, the compulsion to use, and dependence[34]. Measured levels of tobacco dependence ranged from ‘Very low dependence’ score 0-2 to ‘Very high dependence’ score 8-10.

Alcohol use was assessed using the Alcohol Use Disorder Identification Test–Consumption (AUDIT–C)[35]. Past 30-day drug use was captured by using a yes/no question. HIV characteristics include years living with HIV and duration of ART use. A history of any chronic disease (e.g., hypertension, diabetes) was obtained from medical charts. Sociodemographic variables included sex, age, marital status, educational status, household income, occupation, and living arrangement (e.g., living with children)

### *Data analysis*

Data were analyzed using Stata (version 14.0). Descriptive statistics were used to summarize PLWH characteristics and prevalence of depression. The dependent variable was defined as “having depressive symptom – Yes/No” with the cutoff point score of CES-D8  $\geq 9$ . Independent variables having a p-value  $< 0.2$  in the bivariate analyses were included in the logistic regression model. We conducted bivariate tests using a significance level of  $\alpha = 0.05$ . Categorical variables were assessed via chi-square tests and continuous variables were assessed using t-tests. Multivariable analysis using logistic regression was used to assess the associations between depression and other patient characteristics. Odds ratios are reported with 95% confidence intervals.

## Patient and public involvement

No patients or members of the public were involved in the design, conduct, reporting, and dissemination of the study.

## Results

A total of 527 PLWH current cigarette smokers who completed baseline surveys were included in the study; 48.6% were cigarette smoker only and 51.4% were dual users (smoking both cigarettes and waterpipe), 95.8% were male and 4.2% were female. This low prevalence of female smokers was consistent with the national data on cigarettes smoking by sex in which only 1.1% female smoked cigarettes[36]; the average PLWH age was 44.3 ( $\pm 7.0$ ); 53.9% PLWH were married and 46.1% were single, separated, divorced, or widowed; 45.7% had less than high school education, 36.6% had a high school education, and 17.7% had a college/university education; 63.4% worked in a small business, trading, services, or freelance, 20.5% worked in the private sector; 29% had an annual household income less than 100 VND millions 59.6% had an annual household income from 100-300 VND millions, and 10.8% had the income more than 300 VND millions (Table 1). The mean duration of HIV diagnosis was 12.5 years ( $\pm 6.4$ ). Sixty two percent of patient ever used drugs and 18.6% used drugs in the last 3 months.

The prevalence of depressive symptoms (CED-8 score  $\geq 9$ ) was 38.3% (Table 1).

**Table 1: Characteristics of PLWH**

Characteristics (N=527)	n	%/Mean $\pm$ SD
<b>Gender</b>		
Female	22	4.2
Male	505	95.8
<b>Age (mean)</b>	527	44.3 $\pm$ 7.0
<b>Marital status</b>		
Single/Separated/Divorced/Widowed	243	46.1
Married	284	53.9
<b>Education</b>		
Less than high school	241	45.7
High school	193	36.6
Vocational training/College/University and above	93	17.7
<b>Occupation</b>		
Private sector employee	108	20.5
Small business/Trading/Services/Freelance	334	63.4

	Other	85	16.1
<b>Household income in the past 12 months</b>			
	50,000,000 - < 100,000,000	153	29.0
	100,000,000 - < 300,000,000	341	59.6
	>=300,000,000	57	10.8
<b>Type of smoker</b>			
	Cigarettes only	256	48.6
	Dual user	271	51.4
<b>Duration of diagnosed with HIV (min=0, max=35)</b>		527	12.5±6.4
<b>Drug use</b>			
	Never used drugs	102	19.4
	Ever used drugs	327	62.0
	Used drugs in the last 3 months	98	18.6
<b>Depressive symptoms</b>			
	No	325	61.7
	Yes	202	38.3

In the bivariate models examining the correlation between depressive symptom and other factors (Table 2), marital status, living arrangement, level of tobacco dependence, self-reported health status, social support were significantly associated with depressive symptoms ( $P < 0.05$ ).

Prevalence of depressive symptoms was lower among smokers living with HIV who were married than among smokers living with HIV who were not married (23.2% vs. 56%,  $P < 0.001$ ).

Prevalence of depressive symptoms was lower among smokers living with HIV who lived with a spouse and children than among those who lived alone or with other (30.9% vs. 54.5% and 57.8%,  $P < 0.001$ ).

Smokers living with HIV who reported fair or poor health status had a higher proportion of having depressive symptoms than smokers living with HIV who reported good, very good, or excellent health status (43.9% vs. 24.2%,  $P < 0.001$ ).

Smokers living with HIV with a high/very high level of tobacco dependence had a higher proportion of having depressive symptoms than smokers living with HIV with a low/very low level of tobacco dependence (46.1% vs. 29.8%,  $P < 0.001$ ).

Smokers living with HIV with depressive symptoms had a lower score on social support than smokers living with HIV not having depressive symptoms (5.0 vs 4.0 with  $P < 0.001$ ).

Results from multivariate analyses presented in table 2 show that marital status, level of tobacco dependence, self-reported health status were significantly associated with depressive symptoms.



Smokers living with HIV who were married were 72% less likely than people who were not married to have depressive symptoms (OR = 0.28, 95% CI 0.17-0.46).

Smokers living with HIV who had a higher level of tobacco dependence were more likely to have depressive symptoms than smokers living with HIV with a lower level of tobacco dependence (OR =1.09, 95% CI 1.01-1.19).

Smokers living with HIV who self-reported their health as fair/poor were 2.35 times more likely to have depression symptoms compared with smokers living with HIV who self-reported their health as good/very good/excellent (OR =2.39, 95% CI 1.48-3.86).

**Table 2: Factors associated with depressive symptoms among PLWH**

Characteristics	Depressive symptoms				OR (95% CI)
	No		Yes		
	n	% /Mean±SD	n	% /Mean±SD	
<b>Gender</b>					
Female	9	40.9	13	59.1*	Ref.
Male	316	62.6	189	37.4	0.45 (0.18-1.16)
<b>Age (mean)</b>	325	44.6±7.0	202	43.8±6.9	
<b>Marital status</b>					
Single/ Never married/Separated/Divorced	107	44.0	136	56.0	Ref.
Married	218	76.7	66	23.2***	<b>0.28***</b> (0.17-0.46)
<b>Education</b>					
Less than high school	151	62.7	90	37.3	
High school	113	58.6	80	41.5	
Vocational training/ College/University and above	61	65.6	32	34.4	
<b>Occupation</b>					
Private sector employee	71	65.7	37	34.3*	Ref.
Small business/ Trading/Services/Freelance	193	57.8	141	42.2	1.16 (0.69-1.93)
Others	61	71.8	24	28.2	0.61 (0.30-1.22)
<b>Household income in the past 12 months</b>					
50,000,000 - < 100,000,000	88	57.5	65	42.5	
100,000,000 - < 300,000,000	200	63.7	114	36.3	
300,000,000 and over 500,000,000	36	63.2	21	36.8	
<b>Living arrangements</b>					
Live alone	20	45.5	24	54.5***	Ref.
Live with spouse/partner/children /grandchildren	257	69.1	115	30.9	0.91 (0.43-1.95)
Live with others	48	43.2	63	57.8	1.05 (0.50-2.22)

\*\*\*  $p$ -value <0.001, \*\*  $p$ -value <0.01, \* $p$ -value <0.05

**Table 2: Factors associated with depressive symptoms among PLWH (Continued)**

Factors	Depressive symptoms				OR (95% CI)
	No		Yes		
	n	% /Mean±SD	n	% /Mean±SD	
<b>Duration of diagnosed with HIV</b>	325	12.4±6.5	202	12.8±6.3	
<b>Duration of ART</b>	325	10.0±5.5	202	10.3±7.9	
<b>Have chronic disease</b>					
No	262	63.6	150	36.4+	Ref.
Yes	63	54.8	52	45.2	1.36 (0.85-2.18)
<b>Current health status</b>					
Good/Very good/Excellent	113	75.8	36	24.2***	Ref.
Fair/Poor	212	56.1	166	43.9	<b>2.39***</b> (1.48-3.86)
<b>Type of smoker</b>					
Cigarettes only	158	61.7	98	38.3	
Dual user	167	61.6	104	38.4	
<b>Tobacco dependence level</b>					
Very low/Low	174	70.2	74	29.8**	
Medium	41	54.7	34	45.3	
High/Very high	110	53.9	94	46.1	
Tobacco dependence (score)	325	4.0±2.6	202	5.0±2.3***	<b>1.09*</b> (1.01-1.19)
<b>Hazardous drinking</b>					
No	112	59.3	77	40.7	
Yes	213	63.0	125	37.0	
<b>Drug use</b>					
Never	73	71.6	29	28.4*	Ref.
Ever	200	61.2	127	38.8	1.16 (0.66-2.02)
In the last 3 months	52	53.1	46	46.9	1.19 (0.61-2.33)
<b>Social support</b>					
Family support score	325	3.2±0.5	202	3.1±0.5	
Friend support score	325	2.9±0.5	202	2.8±0.5	
Other support score	325	3.2±0.5	202	3.1±0.5*	
<b>Total social support score (min-max: 1.33-4.33)</b>	325	3.4±0.4	202	3.3±0.4*	0.86 (0.55-1.37)

\*\*\*  $p$ -value < 0.001, \*\*  $p$ -value < 0.01, \*  $p$ -value < 0.05

## Discussion

Our study found a high prevalence of depressive symptoms (38.3%) among PLWH who smoke and are receiving HIV care and treatment at OPCs in Viet Nam. This is 16 times higher than the prevalence of depression in the general population in Vietnam (2.5%) [37].

Patients with higher levels of tobacco dependence were more likely to report higher level of depressive symptoms. The literature on the direction of this relationship is inconsistent [38-40]. PLWH with depression may use nicotine to elevate their mood. Alternatively, smoking may lead to depression through changes in the brain's susceptibility to environmental stress [40, 41]. Concern among clinicians about exacerbating depression symptoms has hindered treatment of tobacco use. However, there is growing evidence that smoking cessation has beneficial effects on mental health symptoms [42]. It is critically important to develop and implement models of care that combine mental health and tobacco cessation in this population.

Consistent with other studies of PLWH, we found that depressive symptoms were less prevalent among smokers living with HIV/AIDS who reported a higher level of social support [17, 43]. Patients who were married were significantly less likely to report significant depressive symptoms compared with those who were single, separated/divorced/widowed. HIV-associated stigma may increase a sense of isolation among those without meaningful relationships and social ties. Our findings are consistent with a study by Badru et al, which suggests that social support, particularly from significant others, may reduce perceived stigma [43]. Support for PLWH is also associated with improved quality of life, reduced depression symptoms and improved ART adherence. More data is needed on effective methods for enhancing social support in the context of HIV care.

Finally, this study, consistent with previous studies [19, 21] finds self-reported poor health was associated with significant depressive symptoms. The direction of this relationship is also not clear, and may be, in part, related to concurrent tobacco use. However, the finding further highlights that optimizing quality of life and health outcomes requires addressing both mental health and tobacco use as part of routine HIV care.

There are limitations to this analysis. First, the cross-sectional design does not allow for conclusions about the direction of these associations. For example, poorer health may contribute to depressive symptoms and vice versa. Second, participants were drawn from a sample of PLWH who were receiving treatment at HIV OPCs. This may therefore not represent the larger population of PLWH in Viet Nam. However, in Viet Nam, most PLWH are received ART at OPCs. Finally, the CES-D 8 is a screening tool rather than a diagnostic instrument, this study could only assess the prevalence of depressive symptoms among PLWH instead of the prevalence of diagnosed depression.

## Conclusions

Based on these findings and prior literature, the high prevalence of co-occurring depression and tobacco use among PLWH and the individual and combined impact on health outcomes, makes it imperative to support HIV treatment settings to integrate screening for both tobaccos use and depression into routine care. Further focusing on enhancing social support, through additional services and programs may facilitate treatment engagement and improve health outcomes [41].

**Contributors:** Designed the study: DS, NN. Developed data collection tools: DS, NN, TN, GG, MA, GV. Collected data: NT, YP. Analyzed data and interpreted results: TN, NT, YP. Wrote the initial draft: NN, DS. Contributed to subsequent drafts: DS, GG, MA, TN, GV. All authors reviewed and approved the final manuscript.

**Funding:** This work was supported by the National Cancer Institute, US National Institutes of Health (grant number R01CA240481).

**Competing interests:** None declared.

**Patient consent for publication:** Not required.

**Ethics approval:** The institutional review boards of the Institute of Social Medical Studies and the New York University School of Medicine.

**Data availability statement:** available upon reasonable request.

## References

1. Organization, W.H. *Factsheet. HIV and AIDS.* (online) 2023. <https://www.who.int/news-room/fact-sheets/detail/hiv-aids> (accessed 6/15/2023).
2. Mdege, N.D., et al., *Tobacco use among people living with HIV: analysis of data from Demographic and Health Surveys from 28 low-income and middle-income countries.* The Lancet Global Health, 2017. **5**(6): p. e578-e592.
3. Mills, E.J., et al., *Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda.* Ann Intern Med, 2011. **155**(4): p. 209-16.
4. Parascandola, M., et al., *Colliding epidemics: research gaps and implementation science opportunities for tobacco use and HIV/AIDS in low-and middle-income countries.* Journal of Smoking Cessation, 2022. **2022**.
5. Nguyen, N.P.T., et al., *Prevalence of cigarette smoking and associated factors in a large sample of HIV-positive patients receiving antiretroviral therapy in Vietnam.* PloS one, 2015. **10**(2): p. e0118185.
6. Abadiga, M., *Depression and its associated factors among HIV/AIDS patients attending ART clinics at Gimbi General hospital, West Ethiopia, 2018.* BMC Res Notes, 2019. **12**(1): p. 527.
7. Ciesla, J.A. and J.E. Roberts, *Meta-analysis of the relationship between HIV infection and risk for depressive disorders.* American journal of psychiatry, 2001. **158**(5): p. 725-730.
8. Mekonen, T., H. Belete, and W. Fekadu, *Depressive symptoms among people with HIV/AIDS in Northwest Ethiopia: comparative study.* BMJ open, 2021. **11**(7): p. e048931.
9. Rabkin, J.G., *HIV and depression: 2008 review and update.* Current Hiv/aids Reports, 2008. **5**: p. 163-171.
10. Ayano, G., L. Tsegay, and M. Solomon, *Food insecurity and the risk of depression in people living with HIV/AIDS: a systematic review and meta-analysis.* AIDS Research and Therapy, 2020. **17**(1): p. 1-11.
11. Gritz, E.R., et al., *Smoking behavior in a low-income multiethnic HIV/AIDS population.* Nicotine & Tobacco Research, 2004. **6**(1): p. 71-77.
12. Brown, T. and K. Morgan, *Psychological distress and substance abuse in Jamaican youths living with HIV/AIDS.* West Indian Medical Journal, 2013. **62**(4).
13. Zhang, C., et al., *Substance Use and Psychosocial Status among People Living with HIV/AIDS Who Encountered HIV Stigma in China: Stratified Analyses by Socio-Economic Status.* PLOS ONE, 2016. **11**(11): p. e0165624.

14. Duko, B., et al., *Prevalence and associated factors of depression among patients with HIV/AIDS in Hawassa, Ethiopia, cross-sectional study*. Ann Gen Psychiatry, 2018. **17**: p. 45.
15. Olanrewaju Gt, I.B.A., *Prevalence and Correlates of Depressive Disorders among People Living with HIV/AIDS, in North Central Nigeria*. Journal of AIDS & Clinical Research, 2013. **04**(01).
16. Esposito, C.A., et al., *The prevalence of depression among men living with HIV infection in Vietnam*. Am J Public Health, 2009. **99 Suppl 2**(Suppl 2): p. S439-44.
17. Matsumoto, S., et al., *Social Support as a Key Protective Factor against Depression in HIV-Infected Patients: Report from large HIV clinics in Hanoi, Vietnam*. Sci Rep, 2017. **7**(1): p. 15489.
18. Huynh, V.N., et al., *Changes in depressive symptoms and correlates in HIV+ people at An Hoa Clinic in Ho Chi Minh City, Vietnam*. BMC Psychiatry, 2017. **17**(1): p. 35.
19. Thai, T.T., et al., *Symptoms of Depression in People Living with HIV in Ho Chi Minh City, Vietnam: Prevalence and Associated Factors*. AIDS Behav, 2018. **22**(Suppl 1): p. 76-84.
20. Green, K., et al., *Integrating palliative care into HIV outpatient clinical settings: preliminary findings from an intervention study in Vietnam*. J Pain Symptom Manage, 2010. **40**(1): p. 31-4.
21. Levintow, S.N., et al., *Prevalence and predictors of depressive symptoms among HIV-positive men who inject drugs in Vietnam*. PLoS One, 2018. **13**(1): p. e0191548.
22. Junaid, K., et al., *Substance Abuse and Mental Health Issues Among HIV/AIDS Patients*. Journal of the College of Physicians and Surgeons--Pakistan: JCPSP, 2023. **33**(3): p. 325-334.
23. Teixeira, L.S.L., et al., *Prevalence of smoking and associated factors in people living with HIV undergoing treatment*. Rev Saude Publica, 2020. **54**: p. 108.
24. Deborah Kacane, D.L.J., Donna Spiegelman, Christine Wanke, Rita Isaac, and Ira B. Wilson, *Incident Depression Symptoms Are Associated With Poorer HAART Adherence: A Longitudinal Analysis From the Nutrition for Healthy Living Study*. Acquir Immune Defic Syndr, 2010. **53**.
25. Do, H.M., et al., *Factors associated with suboptimal adherence to antiretroviral therapy in Viet Nam: a cross-sectional study using audio computer-assisted self-interview (ACASI)*. BMC Infect Dis, 2013. **13**: p. 154.
26. Meade, C.S. and K.J. Sikkema, *HIV risk behavior among adults with severe mental illness: a systematic review*. Clinical psychology review, 2005. **25**(4): p. 433-457.
27. Ryan, K., et al., *Depressive symptoms as a link between barriers to care and sexual risk behavior of HIV-infected individuals living in non-urban areas*. AIDS care, 2008. **20**(3): p. 331-336.
28. Antelman, G., et al., *Depressive symptoms increase risk of HIV disease progression and mortality among women in Tanzania*. J Acquir Immune Defic Syndr, 2007. **44**(4): p. 470-7.
29. Kingori, C., Z.T. Haile, and P. Ngatia, *Depression symptoms, social support and overall health among HIV-positive individuals in Kenya*. Int J STD AIDS, 2015. **26**(3): p. 165-72.
30. Radloff, L.S., *The CES-D scale: A self-report depression scale for research in the general population*. Applied psychological measurement, 1977. **1**(3): p. 385-401.
31. Briggs, R., et al., *Validation of the 8-item Centre for Epidemiological Studies Depression Scale in a cohort of community-dwelling older people: data from The Irish Longitudinal Study on Ageing (TILDA)*. Eur Geriatr Med, 2018. **9**(1): p. 121-126.
32. Herdman, M., et al., *Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)*. Quality of life research, 2011. **20**(10): p. 1727-1736.
33. Zimet, G.D., et al., *The multidimensional scale of perceived social support*. Journal of personality assessment, 1988. **52**(1): p. 30-41.
34. Heatherton, T.F., et al., *The Fagerström test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire*. British journal of addiction, 1991. **86**(9): p. 1119-1127.

- 1 35. Bush, K., et al., *The AUDIT alcohol consumption questions (AUDIT-C): an effective brief*  
2 *screening test for problem drinking*. Archives of internal medicine, 1998. **158**(16): p.  
3 1789-1795.
- 4 36. Van Minh, H., et al., *Prevalence of tobacco smoking in Vietnam: findings from the Global*  
5 *Adult Tobacco Survey 2015*. Int J Public Health, 2017. **62**(Suppl 1): p. 121-129.
- 6 37. Organization, W.H. *Factsheet. Mental Health in Vietnam*. (online) 2023.  
7 <https://www.who.int/vietnam/health-topics/mental-health> (accessed 6/15/2023).
- 8 38. Prochaska, J.J., *Smoking and mental illness—breaking the link*. New England Journal of  
9 Medicine, 2011. **365**(3): p. 196-198.
- 10 39. Leventhal, A.M. and M.J. Zvolensky, *Anxiety, depression, and cigarette smoking: A*  
11 *transdiagnostic vulnerability framework to understanding emotion–smoking comorbidity*.  
12 Psychological bulletin, 2015. **141**(1): p. 176.
- 13 40. Fluharty, M., et al., *The Association of Cigarette Smoking With Depression and Anxiety:*  
14 *A Systematic Review*. Nicotine Tob Res, 2017. **19**(1): p. 3-13.
- 15 41. Rubin, L.F., et al., *Depression as a moderator of the prospective relationship between*  
16 *mood and smoking*. Health Psychology, 2020. **39**(2): p. 99.
- 17 42. Taylor, G., et al., *Change in mental health after smoking cessation: systematic review*  
18 *and meta-analysis*. Bmj, 2014. **348**.
- 19 43. Badru, O.A. and O.E. Babalola, *Significant Others and Not Family or Friend Support*  
20 *Mediate Between Stigma and Discrimination Among People Living With HIV in Lagos*  
21 *State, Nigeria: A Cross-sectional Study*. Journal of the Association of Nurses in AIDS  
22 Care, 2023. **34**(1): p. 96-104.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# Reporting checklist for cross sectional study.

Based on the STROBE cross sectional guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cross sectional reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

		Reporting Item	Page Number
<b>Title and abstract</b>			
Title	<a href="#">#1a</a>	Indicate the study's design with a commonly used term in the title or the abstract	1
Abstract	<a href="#">#1b</a>	Provide in the abstract an informative and balanced summary of what was done and what was found	1
<b>Introduction</b>			
Background / rationale	<a href="#">#2</a>	Explain the scientific background and rationale for the investigation being reported	2
Objectives	<a href="#">#3</a>	State specific objectives, including any prespecified hypotheses	2
<b>Methods</b>			
Study design	<a href="#">#4</a>	Present key elements of study design early in the paper	2
Setting	<a href="#">#5</a>	Describe the setting, locations, and relevant dates, including periods of	2

		recruitment, exposure, follow-up, and data collection	
1			
2	Eligibility criteria	<a href="#">#6a</a> Give the eligibility criteria, and the sources and methods of selection of	2
3		participants.	
4			
5			
6		<a href="#">#7</a> Clearly define all outcomes, exposures, predictors, potential	3
7		confounders, and effect modifiers. Give diagnostic criteria, if applicable	
8			
9			
10	Data sources /	<a href="#">#8</a> For each variable of interest give sources of data and details of methods	3
11	measurement	of assessment (measurement). Describe comparability of assessment	
12		methods if there is more than one group. Give information separately	
13		for for exposed and unexposed groups if applicable.	
14			
15			
16	Bias	<a href="#">#9</a> Describe any efforts to address potential sources of bias	3
17			
18			
19	Study size	<a href="#">#10</a> Explain how the study size was arrived at	2
20			
21	Quantitative	<a href="#">#11</a> Explain how quantitative variables were handled in the analyses. If	3
22	variables	applicable, describe which groupings were chosen, and why	
23			
24			
25	Statistical	<a href="#">#12a</a> Describe all statistical methods, including those used to control for	3
26	methods	confounding	
27			
28			
29	Statistical	<a href="#">#12b</a> Describe any methods used to examine subgroups and interactions	3
30	methods		
31			
32			
33	Statistical	<a href="#">#12c</a> Explain how missing data were addressed	3
34	methods		
35			
36			
37	Statistical	<a href="#">#12d</a> If applicable, describe analytical methods taking account of sampling	3
38	methods	strategy	
39			
40			
41	Statistical	<a href="#">#12e</a> Describe any sensitivity analyses	3
42	methods		
43			
44	<b>Results</b>		
45			
46	Participants	<a href="#">#13a</a> Report numbers of individuals at each stage of study—eg numbers	4
47		potentially eligible, examined for eligibility, confirmed eligible,	
48		included in the study, completing follow-up, and analysed. Give	
49		information separately for for exposed and unexposed groups if	
50		applicable.	
51			
52			
53			
54			
55	Participants	<a href="#">#13b</a> Give reasons for non-participation at each stage	4
56			
57	Participants	<a href="#">#13c</a> Consider use of a flow diagram	4
58			
59			
60			



1	Descriptive data	<a href="#">#14a</a>	Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders. Give information separately for exposed and unexposed groups if applicable.	4
2				
3				
4				
5				
6	Descriptive data	<a href="#">#14b</a>	Indicate number of participants with missing data for each variable of interest	4
7				
8				
9				
10	Outcome data	<a href="#">#15</a>	Report numbers of outcome events or summary measures. Give information separately for exposed and unexposed groups if applicable.	5
11				
12				
13				
14	Main results	<a href="#">#16a</a>	Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	4-7
15				
16				
17				
18				
19	Main results	<a href="#">#16b</a>	Report category boundaries when continuous variables were categorized	4-7
20				
21	Main results	<a href="#">#16c</a>	If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	4-7
22				
23				
24				
25	Other analyses	<a href="#">#17</a>	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	4-7
26				
27				
28				
29	<b>Discussion</b>			
30				
31	Key results	<a href="#">#18</a>	Summarise key results with reference to study objectives	8
32				
33				
34	Limitations	<a href="#">#19</a>	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.	8
35				
36				
37				
38				
39	Interpretation	<a href="#">#20</a>	Give a cautious overall interpretation considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.	8
40				
41				
42				
43				
44	Generalisability	<a href="#">#21</a>	Discuss the generalisability (external validity) of the study results	8
45				
46				
47	<b>Other</b>			
48	<b>Information</b>			
49				
50				
51	Funding	<a href="#">#22</a>	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	8
52				
53				
54				
55				

The STROBE checklist is distributed under the terms of the Creative Commons Attribution License CC-BY.

This checklist was completed on 23. June 2023 using <https://www.goodreports.org/>, a tool made by the

[EQUATOR Network](#) in collaboration with [Penelope.ai](#)

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

# BMJ Open

## Depression and associated factors among HIV-positive smokers receiving care at HIV outpatient clinics in Vietnam: a cross-sectional analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-077015.R1
Article Type:	Original research
Date Submitted by the Author:	21-Nov-2023
Complete List of Authors:	Nguyen, Nam; Institute of Social and Medical Studies Nguyen, Trang; Institute of Social and Medical Studies Vu, Giap; Bach Mai Hospital Truong, Nga; Institute of Social and Medical Studies Pham, Yen; Institute of Social and Medical Studies Guevara Alvarez, Gloria; New York University Armstrong-Hough, Mari ; New York University R Shelley, Donna; New York University
<b>Primary Subject Heading</b>:	Mental health
Secondary Subject Heading:	HIV/AIDS, Smoking and tobacco
Keywords:	Depression & mood disorders < PSYCHIATRY, HIV & AIDS < INFECTIOUS DISEASES, MENTAL HEALTH, PUBLIC HEALTH

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

## Depression and associated factors among HIV-positive smokers receiving care at HIV outpatient clinics in Vietnam: a cross-sectional analysis

Nam Truong Nguyen<sup>1</sup>, Trang Nguyen<sup>1</sup>, Giap Van Vu<sup>3</sup>, Nga Truong<sup>1</sup>, Yen Pham<sup>1</sup>, Gloria Guevara Alvarez<sup>2</sup>, Mari Armstrong-Hough<sup>2</sup>, Donna Shelley<sup>2</sup>

<sup>1</sup>Institute of Social and Medical Studies, Ha Noi, Vietnam

<sup>2</sup>School of Global Public Health, New York University, New York, NY, USA

<sup>3</sup>Bach Mai Hospital, Ha Noi, Vietnam

### Corresponding author

Nam Truong Nguyen

[ntnam@isms.org.vn](mailto:ntnam@isms.org.vn)

### ABSTRACT

#### Objectives

Assess the prevalence of depressive symptoms and associated factors among people living with HIV (PLWH) who are current cigarette smokers receiving treatment at HIV outpatient clinics (OPCs) in Vietnam.

**Design:** A cross-sectional survey of smokers living with HIV.

**Setting:** 13 HIV outpatient clinics in Ha Noi, Vietnam

#### Participants:

A total of 527 people living with HIV aged 18 and above, who were smokers and were receiving treatment at HIV outpatient clinics, were included in the study.

#### Outcome measures:

The Center for Epidemiology Scale for Depression (CES-D 8) was used to assess depressive symptoms. Bivariate and Poisson regression analyses were used to assess the association between depressive symptoms, tobacco dependence, and other characteristics.

#### Results

The prevalence of depressive symptoms among smokers living with HIV was 38.3%. HIV-positive smokers who were female (PR=1.51, 95% CI 1.02-2.22), unmarried (PR = 2.06, 95% CI 1.54-2.76), had a higher level of tobacco dependence (PR =1.06, 95% CI 1.01-1.11), and reported their health as fair/poor (PR =1.66, 95% CI 1.22-2.26) were more likely to have depression symptoms compared with HIV-positive smokers who were male, married, had a lower level of tobacco dependence, and self-reported their health as good/very good/excellent.

#### Conclusion

The prevalence of depressive symptoms among smokers receiving HIV care at OPCs was high. Both depression and tobacco use screening and treatment should be included as part of ongoing care treatment plans at HIV OPCs.

**Keywords:** Depression; depressive symptoms; tobacco use; HIV; people living with HIV; Vietnam; low-and middle-income country.

### Strengths and limitations of this study

- The study used the CES-D 8, a validated scale to screen depressive symptoms, with a large sample of smokers living with HIV and receiving treatment in HIV outpatient clinics.
- The CES-D 8 is a screening tool rather than a diagnostic instrument, therefore this study could only assess the prevalence of depressive symptoms among PLWH instead of the prevalence of diagnosed depression.
- The study employed Poisson regression (estimating Prevalence Ratios), a more robust alternative for the analysis of cross-sectional studies with binary outcomes than logistic regression (reporting Odd Ratios).
- The cross-sectional design did not allow for conclusions about the direction of the associations between depression and other factors.
- The study sample, which included PLWH who were receiving treatment at HIV OPCs, may not represent the larger population of PLWH in Vietnam.

## INTRODUCTION

HIV infection remains a major public health issue, with over 38 million people living with HIV (PLWH) globally [1]. With increased access to antiretroviral medication, HIV infection has become a manageable chronic health condition, with a lifespan comparable to that of the general population [2, 3]. However, gains in life expectancy are threatened by the growing burden of non-communicable diseases (NCDs) among PLWH [4]. This is in part due to high rates of tobacco use in this population, particularly in LMIC countries like Vietnam, where smoking prevalence among male PLWH is over 50% [4, 5]. PLWH who use tobacco are at increased risk of HIV and non-HIV-related chronic diseases that include cancer and cardiovascular diseases compared to PLWH who do not smoke [6].

PLWH experience other risk factors for poor health that include higher rates of depression compared with the general population [7-9]. Prevalence estimates for depression among PLWH range widely from 25.6% to 56.7% [6, 10-15]. Studies conducted in Viet Nam show a similarly high prevalence of depression among PLWH, ranging from 18.7% to 44% [16-21].

Depression is common among smokers, particularly among smokers living with HIV [22, 23]. The high co-occurrence of smoking and depression in this population is a major public health concern. Depression can compromise smoking cessation, negatively impacts adherence to ART, and is associated with faster progression of the disease and greater risk of other health risk behaviors, including alcohol abuse and drug use and poorer health outcomes [22, 24-29].

Despite the deleterious effects of the co-occurrence of depression and tobacco use on health outcomes among PLWH, there is a lack of data on the correlates of depression in this population. To begin to fill this gap in research, we conducted a cross-sectional analysis of factors associated with depressive symptoms among PLWH who smoked and were receiving treatment in HIV outpatient clinics in Ha Noi, Vietnam.

## METHODS

### Study design

We conducted a cross-sectional analysis of data obtained from a quantitative survey of 527 smokers living with HIV. Data were collected between 12/2022 and 6/2023. The sample is a subset of participants taking part in a randomized controlled trial that compared the effectiveness of three smoking cessation interventions delivered in 13 HIV OPCs in Ha Noi, Vietnam. Participants were screened for tobacco use at the time of registration for a routine visit. Participants were eligible to enroll if they were 18 years of age or over, active patients at the OPCs, current cigarette-only or dual users (waterpipe and cigarettes), had a mobile phone, and lived in Ha Noi. An analysis of patients who declined to participate demonstrated no significant differences in gender, age, and smoking status compared with those who enrolled.

The survey was administered in person using a structured questionnaire in Vietnamese. Signed informed consent was obtained from all respondents. The institutional review boards of the Institute of Social Medical Studies (Decision 08/HDDD-ISMS) and the New York University School of Medicine (ID i19-01783) approved this research.

## Measures

### Dependent variable

The 8-item Center for Epidemiology Scale for Depression (CES-D 8) was used to assess depressive symptoms[30]. The CES-D 8 was validated and used in Vietnam[31]. In this study, the internal consistency of CES-D 8 was good with a Cronbach's alpha of 0.76.

Respondents were asked to rate how much of the time during the past week they experienced the following behaviors or feelings: (1) "I felt depressed"; (2) "I felt everything I did was an effort"; (3) "My sleep was restless"; (4) "I was happy"; (5) "I felt lonely"; (6) "I enjoyed life"; (7) "I felt sad"; (8) "I could not get going". Responses were coded as 0=Rarely or none of the time (less than 1 day); 1= Some or a little of the time (1-2 days); 2= Occasionally or a moderate amount of time (3-4 days); 3= Most or all of the time (5-7 days). These responses resulted in scores ranging from 0 to 24. A score of  $\geq 9$  identifies people with depressive symptoms[32].

### Independent variables

Health status was measured using a self-rated health question asking respondents to assess their health status that included 1 = Poor, 2=Fair, 3 = Good, 4 = Very Good, and 5 = Excellent [33].

Social support was assessed using the Multidimensional Scale of Perceived Social Support Scale (MPSS)[34], which aggregates three types of social support which include significant other, family, and friends. Respondents were asked to rate 12 social support statements. Responses ranged from 1 "Strongly disagree" to 4 "Strongly agree". Mean scores were calculated for each of the three social support categories.

Tobacco dependence was assessed using the Fagerstrom Test for Nicotine Dependence which includes six items that evaluate the quantity of cigarette consumption, the compulsion to use, and dependence[35]. Measured levels of tobacco dependence ranged from a 'Very low dependence' score of 0-2 to a 'Very high dependence' score of 8-10.

Alcohol use was assessed using the Alcohol Use Disorder Identification Test-Consumption (AUDIT-C)[36]. The AUDIT-C is scored on a scale of 0-12 (scores of 0 reflect no alcohol use). Hazardous drinking was defined with a score of  $\geq 4$  among men and  $\geq 3$  among women[37].

1 Drug use was defined as the use of substances for psychotropic rather than medical purposes and  
2 was assessed with 2 questions that asked if respondents ever used and used in the past 3 months  
3 any Opium, Cocaine, Heroin, Amphetamine/Methamphetamine, Marijuana, Ecstasy, MDMA,  
4 and Ketamine.

5 HIV characteristics include years of living with HIV and duration of ART use. Having chronic  
6 diseases was assessed using one question that asked if the respondent has ever been diagnosed  
7 with any chronic diseases of High blood pressure, Diabetes, Cancer, and Lung diseases.  
8 Sociodemographic variables included sex, age, marital status, educational status, household  
9 income, occupation, and living arrangement (e.g., living with children).

## 11 Data analysis

12 Data were analyzed using Stata (version 14.0). Descriptive statistics were used to summarize  
13 PLWH characteristics and the prevalence of depressive symptoms. We conducted bivariate tests  
14 using a significance level of 0.05. Categorical variables were assessed via chi-square tests and  
15 continuous variables were assessed using t-tests. Multivariable analysis used Poisson  
16 regression[38] to assess the associations between depression and other patient characteristics.  
17 Prevalence ratios (PR) were reported with 95% confidence intervals. Independent variables that  
18 had a p-value < 0.2 in the bivariate analyses were included in the logistic regression model [39].  
19 P values < 0.05 were considered statistically significant.

## 21 Patient and public involvement

22 No patients or members of the public were involved in the design, conduct, reporting, and  
23 dissemination of the study.

## 24 RESULTS

### 25 Socio-demographic characteristics of the participants

26 A total of 527 PLWH were included in the study, of which 95.8% were male and 4.2% were  
27 female. This low prevalence of female smokers was consistent with the national data on cigarette  
28 smoking by sex in which only 1.1% of females smoked cigarettes[40]. The average PLWH's age  
29 was 44.3 ( $\pm 7.0$ ). In terms of marital status and living arrangements, 53.9% were married, 46.1%  
30 were single, separated, divorced, or widowed, and 70.6% lived with spouses/partners/children.  
31 Regarding education, employment, and income, 45.7% had less than a high school education,  
32 63.4% worked in a small business, trading, services, or freelance, and 59.6% had an annual  
33 household income from 100-300 VND million (Table 1).

34 The mean durations of HIV diagnosis and ART treatment were 12.5 years ( $\pm 6.4$ ) and 10.1 years  
35 ( $\pm 6.5$ ).

36 In terms of health behavior, 48.6% were cigarette smokers only, 51.4% were dual users (smoking  
37 both cigarettes and waterpipe), 38.7% had a high/very high tobacco dependence level, 55% had  
38 hazardous drinking, 62% ever used drugs, and 18.6% used drugs in the last 3 months.

39 Regarding health status, 71.7% reported very poor or poor health status, and 21.8% had chronic  
40 diseases.

### 41 Prevalence and associated factors of depressive symptoms

42 The prevalence of depressive symptoms (CED-8 score  $\geq 9$ ) was 38.3% (Table 1).

43 Table 1 shows the results of bivariate analyses examining the correlation between depressive  
44 symptoms and other factors. The prevalence of depressive symptoms was higher among PLWH  
45 who were female, unmarried, worked in small business/trading/services/freelance, lived alone,

reported a fair/poor health status, had higher tobacco dependence levels, used drugs in the past 3 months, had lower social support compared with those who were male, married, worked in the private sector or other, lived with spouse/partner/children or with others, reported a good/very good/excellent health status, had lower levels of tobacco dependence, never used drugs, and had higher social support.

Results from multivariate analyses presented in Table 2, show that gender, marital status, level of tobacco dependence, and self-reported health status were significantly associated with depressive symptoms.

The probability of having depressive symptoms was significantly higher among females (PR=1.51, 95% CI 1.02-2.22), patients who were unmarried (PR = 2.06, 95% CI 1.54-2.76), and those with higher levels of tobacco dependence (PR =1.06, 95% CI 1.01-1.11), those with a fair/poor health status (PR =1.66, 95% CI 1.22-2.26), compared with patients who were males, married, had a lower level of tobacco dependence, and reported their health as good/very good/excellent).

**Table 1: PLWH's characteristics and bivariate analysis of factors associated with depressive symptoms**

Characteristics	Total		Depressive symptoms				P value
	n	% /Mean ±SD	No		Yes		
			n	% /Mean±SD	n	% /Mean±SD	
<b>Gender</b>							
Female	22	4.2	9	40.9	13	59.1	0.041
Male	505	95.8	316	62.6	189	37.4	
<b>Age (mean)</b>	527	44.3±7.0	325	44.6±7.0	202	43.8±6.9	0.174
<b>Marital status</b>							
Single/ Never married/Separated/Divorced	243	46.1	107	44.0	136	56.0	<0.001
Married	284	53.9	218	76.8	66	23.2	
<b>Education</b>							
Less than high school	241	45.7	151	62.7	90	37.3	0.473
High school	193	36.6	113	58.6	80	41.4	
Vocational training/ College/University and above	93	17.7	61	65.6	32	34.4	
<b>Occupation</b>							
Private sector	108	20.5	71	65.7	37	34.3	0.038
Small business/ Trading/Services/Freelance	334	63.4	193	57.8	141	42.2	
Others	85	16.1	61	71.8	24	28.2	
<b>Household income in the past 12 months</b>							
50,000,000 - < 100,000,000	153	29.0	88	57.5	65	42.5	0.425
100,000,000 - < 300,000,000	314	59.6	200	63.7	114	36.3	
300,000,000 and over 500,000,000	57	10.8	36	63.2	21	36.8	



Characteristics	Total		Depressive symptoms				P value
	n	% /Mean ±SD	No		Yes		
			n	% /Mean±SD	n	% /Mean±SD	
<b>Living arrangements</b>							
Live alone	44	8.3	20	45.5	24	54.5	<0.001
Live with spouse/partner/children /grandchildren	372	70.6	257	69.1	115	30.9	
Live with others	111	21.1	48	43.2	63	56.8	
<b>Duration of diagnosed with HIV</b>	527	12.5±6.4	325	12.4±6.5	202	12.8±6.3	0.449
<b>Duration of ART</b>	527	10.1±6.5	325	10.0±5.5	202	10.3±7.9	0.643
<b>Have depressive symptoms</b>							
No	325	61.7					
Yes	202	38.3					
<b>Have chronic disease</b>							
No	412	78.2	262	63.6	150	36.4	0.086
Yes	115	21.8	63	54.8	52	45.2	
<b>Current health status</b>							
Good/Very good/Excellent	149	28.3	113	75.8	36	24.2	<0.001
Fair/Poor	378	71.7	212	56.1	166	43.9	
<b>Type of smoker</b>							
Cigarettes only	256	48.6	158	61.7	98	38.3	0.982
Dual user	271	51.4	167	61.6	104	38.4	
<b>Tobacco dependence level</b>							
Very low/Low	248	47.1	174	70.2	74	29.8	0.001
Medium	75	14.2	41	54.7	34	45.3	
High/Very high	204	38.7	110	53.9	94	46.1	
Tobacco dependence (score)	527	4.4±2.5	325	4.0±2.6	202	5.0±2.3	<0.001
<b>Hazardous drinking</b>							
No	237	45.0	136	57.4	101	42.6	0.067
Yes	290	55.0	189	65.2	101	34.8	
<b>Drug use</b>							
Never	102	19.4	73	71.6	29	28.4	0.026
Ever	327	62.1	200	61.2	127	38.8	
In the last 3 months	98	18.6	52	53.1	46	46.9	
<b>Social support</b>							
Family support score	527	3.2±0.5	325	3.2±0.5	202	3.1±0.5	0.100
Friend support score	527	2.9±0.6	325	2.9±0.5	202	2.8±0.5	0.211
Other support score	527	3.2±0.5	325	3.2±0.5	202	3.1±0.5	0.041
<b>Total social support score (min-max: 1.33-4.33)</b>	527	3.3±0.4	325	3.4±0.4	202	3.3±0.4	0.038

**Table 2: Multivariate analysis of factors associated with depressive symptoms among PLWH using Poisson regression**

Characteristics	PR (95% CI)	P value
<b>Gender</b>		
Male (ref.)	-	
Female	1.51 (1.02-2.22)	<b>0.039</b>
<b>Age (mean)</b>	1.00 (0.99-1.02)	0.914
<b>Marital status</b>		
Married (ref.)	-	
Single/ Never married/Separated/Divorced	2.06 (1.54-2.76)	<b>&lt;0.001</b>
<b>Occupation</b>		
Private sector (ref.)	-	
Small business/ Trading/Services/Freelance	1.08 (0.82-1.42)	0.583
Others	0.75 (0.50-1.12)	0.166
<b>Living arrangements</b>		
Live alone (ref.)	-	
Live with spouse/partner/children /grandchildren	0.96 (0.68-1.35)	0.819
Live with others	1.04 (0.75-1.44)	0.815
<b>Have chronic disease</b>		
No (ref.)	-	
Yes	1.16 (0.94-1.45)	0.161
<b>Current health status</b>		
Good/Very good/Excellent (ref.)	-	
Fair/Poor	1.66 (1.22-2.26)	<b>0.001</b>
<b>Tobacco dependence (score)</b>	1.06 (1.01-1.11)	<b>0.014</b>
<b>Hazardous drinking</b>		
No (ref.)	-	
Yes	0.86 (0.71-1.05)	0.150
<b>Drug use</b>		
Never (ref.)	-	
Ever	1.08 (0.78-1.49)	0.647
In the last 3 months	1.08 (0.76-1.53)	0.686
<b>Total social support score</b>	0.91 (0.72-1.15)	0.411

## DISCUSSION

1  
2 This study found a high prevalence of depressive symptoms (38.3%) among PLWH who smoke  
3 and are receiving HIV care in OPCs in Vietnam. This is 16 times higher than previous reports of  
4 depressive symptoms in the general Vietnamese population (2.5%) [41]. Our findings are  
5 consistent with prior studies showing a high prevalence of depressive symptoms among PLWH  
6 compared with the general population [42, 43].  
7

8  
9 Depression is the most common mental health problem among PLWH [44, 45]. HIV-associated  
10 biological factors and psychosocial factors that include HIV stigma, occupational disability,  
11 financial difficulties, discrimination, isolation, and debilitation are the causes of the high  
12 prevalence of depressive symptoms in this population [46]. Perceived and experienced stigma and  
13 discrimination are associated with an increased risk of depression among PLWH [47-49].  
14

15  
16 Smokers living with HIV with higher levels of tobacco dependence were more likely to report  
17 higher levels of depressive symptoms compared with smokers living with HIV who had a lower  
18 level of tobacco dependence. The literature on the direction of this relationship is inconsistent [50-  
19 52]. PLWH with depression may use nicotine to elevate their mood. Alternatively, smoking may  
20 lead to depression through changes in the brain's susceptibility to environmental stress [52, 53].  
21 Concern among clinicians about exacerbating depression symptoms has hindered the treatment of  
22 tobacco use. However, there is growing evidence that smoking cessation has beneficial effects on  
23 mental health symptoms [54]. It is critically important to develop and implement models of care  
24 that combine mental health and tobacco cessation in this population.  
25

26  
27 The prevalence of depressive symptoms among female smokers living with HIV was higher than  
28 that among male smokers living with HIV. This finding is consistent with previous studies that  
29 depression is more common among women with HIV compared to the general population, women  
30 without HIV [55], and men with HIV [56-58]. Genetic vulnerability, reproductive hormones,  
31 internalization coping strategies, gender-specific roles, and life stress account for the higher risk  
32 of depression among women [59, 60]. In addition to the biological vulnerabilities, women living  
33 with HIV experience higher levels of perceived stress, and higher levels of HIV stigma [56]. These  
34 increased stressors may consequently contribute to an increased risk of depression among women  
35 with HIV.  
36

37  
38 Consistent with other studies of PLWH [8, 61], this study found a higher prevalence of depressive  
39 symptoms among unmarried smokers living with HIV. Having a diagnosis of HIV, a disease that  
40 is associated with high levels of perceived stigma, may prevent PLWH from getting married and  
41 maintaining a marital relationship. HIV-associated stigma may lead to social isolation and  
42 loneliness among those without meaningful relationships and social ties [62]. Increased loneliness  
43 and isolation along with a lack of psychological and tangible support may increase the risk of  
44 depression among PLWH who are not married. Social support, particularly from significant others,  
45 may reduce perceived stigma and consequently reduce the risk of depression [63]. Support for  
46 PLWH is also associated with improved quality of life, reduced depression symptoms, and  
47 improved ART adherence. More data is needed on effective methods for enhancing social support  
48 in the context of HIV care.  
49

50  
51 Finally, this study, consistent with previous studies [19, 21] finds that self-reported poor health  
52 was associated with significant depressive symptoms. The direction of this relationship is also not  
53 clear and may be, in part related to concurrent tobacco use. However, the finding further highlights  
54 that optimizing quality of life and health outcomes requires addressing both mental health and  
55 tobacco use as part of routine HIV care.  
56  
57

There are limitations to this analysis. First, the cross-sectional design does not allow for conclusions about the direction of these associations. For example, poorer health may contribute to depressive symptoms and vice versa. Second, participants were drawn from a sample of PLWH who were receiving treatment at HIV OPCs. This may, therefore, not represent the larger population of PLWH in Vietnam. However, in Vietnam, most PLWHs receive ART at OPCs. Finally, the CES-D 8 is a screening tool rather than a diagnostic instrument. This study, therefore, could only assess the prevalence of depressive symptoms among PLWH instead of the prevalence of diagnosed depression.

## CONCLUSIONS

Based on these findings and prior literature, the high prevalence of co-occurring depression and tobacco use among PLWH and the individual and combined impact on health outcomes makes it imperative to support HIV treatment settings to integrate screening for both tobacco use and depression into routine care. Further focusing on enhancing social support through additional services and programs may facilitate treatment engagement and improve health outcomes [53].

**Contributors:** Designed the study: DS, NN. Developed data collection tools: DS, NN, TN, GG, MA, GV. Collected data: NT, YP. Analyzed data and interpreted results: TN, NT, YP. Wrote the initial draft: NN, DS. Contributed to subsequent drafts: DS, GG, MA, TN, GV. All authors reviewed and approved the final manuscript.

**Funding:** This work was supported by the National Cancer Institute, US National Institutes of Health (grant number R01CA240481).

**Competing interests:** None declared.

**Patient consent for publication:** Not required.

**Ethics approval:** The institutional review boards of the Institute of Social Medical Studies (Decision 08/HDDD-ISMS) and the New York University School of Medicine (ID i19-01783).

**Data availability statement:** available upon reasonable request.

## REFERENCES

1. World Health Organization. Factsheet. HIV and AIDS 2023 [Available from: <https://www.who.int/news-room/fact-sheets/detail/hiv-aids>].
2. Mdege ND, Shah S, Ayo-Yusuf OA, Hakim J, Siddiqi K. Tobacco use among people living with HIV: analysis of data from Demographic and Health Surveys from 28 low-income and middle-income countries. *The Lancet Global Health*. 2017;5(6):e578-e92.
3. Mills EJ, Bakanda C, Birungi J, Chan K, Ford N, Cooper CL, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. *Ann Intern Med*. 2011;155(4):209-16.
4. Parascandola M, Neta G, Bloch M, Gopal S. Colliding epidemics: research gaps and implementation science opportunities for tobacco use and HIV/AIDS in low-and middle-income countries. *Journal of Smoking Cessation*. 2022;2022.
5. Nguyen NPT, Tran BX, Hwang LY, Markham CM, Swartz MD, Phan HTT, et al. Prevalence of cigarette smoking and associated factors in a large sample of HIV-positive patients receiving antiretroviral therapy in Vietnam. *PloS one*. 2015;10(2):e0118185.

6. Abadiga M. Depression and its associated factors among HIV/AIDS patients attending ART clinics at Gimbi General hospital, West Ethiopia, 2018. *BMC Res Notes*. 2019;12(1):527.
7. Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. *American journal of psychiatry*. 2001;158(5):725-30.
8. Mekonen T, Belete H, Fekadu W. Depressive symptoms among people with HIV/AIDS in Northwest Ethiopia: comparative study. *BMJ Open*. 2021;11(7):e048931.
9. Rabkin JG. HIV and depression: 2008 review and update. *Current Hiv/aids Reports*. 2008;5:163-71.
10. Ayano G, Tsegay L, Solomon M. Food insecurity and the risk of depression in people living with HIV/AIDS: a systematic review and meta-analysis. *AIDS Research and Therapy*. 2020;17(1):1-11.
11. Gritz ER, Vidrine DJ, Lazev AB, Amick BC, Arduino RC. Smoking behavior in a low-income multiethnic HIV/AIDS population. *Nicotine & Tobacco Research*. 2004;6(1):71-7.
12. Brown T, Morgan K. Psychological distress and substance abuse in Jamaican youths living with HIV/AIDS. *West Indian Medical Journal*. 2013;62(4).
13. Zhang C, Li X, Liu Y, Qiao S, Zhou Y, Shen Z, et al. Substance Use and Psychosocial Status among People Living with HIV/AIDS Who Encountered HIV Stigma in China: Stratified Analyses by Socio-Economic Status. *PLOS ONE*. 2016;11(11):e0165624.
14. Duko B, Geja E, Zewude M, Mekonen S. Prevalence and associated factors of depression among patients with HIV/AIDS in Hawassa, Ethiopia, cross-sectional study. *Ann Gen Psychiatry*. 2018;17:45.
15. Olanrewaju Gt IBA. Prevalence and Correlates of Depressive Disorders among People Living with HIV/AIDS, in North Central Nigeria. *Journal of AIDS & Clinical Research*. 2013;04(01).
16. Esposito CA, Steel Z, Gioi TM, Huyen TT, Tarantola D. The prevalence of depression among men living with HIV infection in Vietnam. *Am J Public Health*. 2009;99 Suppl 2(Suppl 2):S439-44.
17. Matsumoto S, Yamaoka K, Takahashi K, Tanuma J, Mizushima D, Do CD, et al. Social Support as a Key Protective Factor against Depression in HIV-Infected Patients: Report from large HIV clinics in Hanoi, Vietnam. *Sci Rep*. 2017;7(1):15489.
18. Huynh VN, To KG, Do DV, To QG, Nguyen MT. Changes in depressive symptoms and correlates in HIV+ people at An Hoa Clinic in Ho Chi Minh City, Vietnam. *BMC Psychiatry*. 2017;17(1):35.
19. Thai TT, Jones MK, Harris LM, Heard RC, Hills NK, Lindan CP. Symptoms of Depression in People Living with HIV in Ho Chi Minh City, Vietnam: Prevalence and Associated Factors. *AIDS Behav*. 2018;22(Suppl 1):76-84.
20. Green K, Tuan T, Hoang TV, Trang NN, Ha NT, Hung ND. Integrating palliative care into HIV outpatient clinical settings: preliminary findings from an intervention study in Vietnam. *J Pain Symptom Manage*. 2010;40(1):31-4.
21. Levintow SN, Pence BW, Ha TV, Minh NL, Sripaipan T, Latkin CA, et al. Prevalence and predictors of depressive symptoms among HIV-positive men who inject drugs in Vietnam. *PLoS One*. 2018;13(1):e0191548.
22. Junaid K, Afzal S, Daood M, Siddiqui M. Substance Abuse and Mental Health Issues Among HIV/AIDS Patients. *Journal of the College of Physicians and Surgeons--Pakistan: JCPSP*. 2023;33(3):325-34.
23. Teixeira LSL, Ceccato M, Carvalho WDS, Costa JO, Bonolo PF, Mendes JC, et al. Prevalence of smoking and associated factors in people living with HIV undergoing treatment. *Rev Saude Publica*. 2020;54:108.
24. Deborah Kacanek DLJ, Donna Spiegelman, Christine Wanke, Rita Isaac, and Ira B. Wilson. Incident Depression Symptoms Are Associated With Poorer HAART Adherence: A Longitudinal Analysis From the Nutrition for Healthy Living Study. *Acquir Immune Defic Syndr*. 2010;53.

25. Do HM, Dunne MP, Kato M, Pham CV, Nguyen KV. Factors associated with suboptimal adherence to antiretroviral therapy in Viet Nam: a cross-sectional study using audio computer-assisted self-interview (ACASI). *BMC Infect Dis*. 2013;13:154.
26. Meade CS, Sikkema KJ. HIV risk behavior among adults with severe mental illness: a systematic review. *Clinical psychology review*. 2005;25(4):433-57.
27. Ryan K, Forehand R, Solomon S, Miller C. Depressive symptoms as a link between barriers to care and sexual risk behavior of HIV-infected individuals living in non-urban areas. *AIDS care*. 2008;20(3):331-6.
28. Antelman G, Kaaya S, Wei R, Mbwambo J, Msamanga GI, Fawzi WW, et al. Depressive symptoms increase risk of HIV disease progression and mortality among women in Tanzania. *J Acquir Immune Defic Syndr*. 2007;44(4):470-7.
29. Kingori C, Haile ZT, Ngatia P. Depression symptoms, social support and overall health among HIV-positive individuals in Kenya. *Int J STD AIDS*. 2015;26(3):165-72.
30. Radloff LS. The CES-D scale: A self-report depression scale for research in the general population. *Applied psychological measurement*. 1977;1(3):385-401.
31. Moulis L, Le SM, Hai VV, Huong DT, Minh KP, Oanh KTH, et al. Gender, homelessness, hospitalization and methamphetamine use fuel depression among people who inject drugs: implications for innovative prevention and care strategies. *Frontiers in Psychiatry*. 2023;14.
32. Briggs R, Carey D, O'Halloran AM, Kenny RA, Kennelly SP. Validation of the 8-item Centre for Epidemiological Studies Depression Scale in a cohort of community-dwelling older people: data from The Irish Longitudinal Study on Ageing (TILDA). *Eur Geriatr Med*. 2018;9(1):121-6.
33. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Quality of life research*. 2011;20(10):1727-36.
34. Zimet GD, Dahlem NW, Zimet SG, Farley GK. The multidimensional scale of perceived social support. *Journal of personality assessment*. 1988;52(1):30-41.
35. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerström test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. *British journal of addiction*. 1991;86(9):1119-27.
36. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. *Archives of internal medicine*. 1998;158(16):1789-95.
37. Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief screen for alcohol misuse in primary care. *Alcohol Clin Exp Res*. 2007;31(7):1208-17.
38. Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. *BMC Med Res Methodol*. 2003;3:21.
39. Vittinghoff E, Shiboski S, Glidden D, McCulloch C. *Regression Methods in Biostatistics: Linear, Logistic, Survival and Repeated Measures Models*. New York: Springer; 2011.
40. Van Minh H, Giang KB, Ngoc NB, Hai PT, Huyen DT, Khue LN, et al. Prevalence of tobacco smoking in Vietnam: findings from the Global Adult Tobacco Survey 2015. *Int J Public Health*. 2017;62(Suppl 1):121-9.
41. World Health Organization. Factsheet. Mental Health in Vietnam [Available from: <https://www.who.int/vietnam/health-topics/mental-health>].
42. Jeffrey A. Ciesla MAJER, Ph.D. *Meta-Analysis of the Relationship Between HIV Infection and Risk for Depressive Disorders*. *Am J Psychiatry*. 2001.
43. Rabkin JG. *HIV and Depression: 2008 Review and Update*. 2008.
44. Adams C, Zacharia S, Masters L, Coffey C, Catalan P. Mental health problems in people living with HIV: changes in the last two decades: the London experience 1990-2014. *AIDS Care*. 2016;28 Suppl 1(sup1):56-9.
45. Gaynes BN, Pence BW, Eron JJ, Miller WC. Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. *Psychosom Med*. 2008;70(4):505-11.

- 1 46. Arseniou S, Arvaniti A, Samakouri M. HIV infection and depression. *Psychiatry Clin Neurosci*. 2014;68(2):96-109.
- 2 47. Tran BX, Dang AK, Truong NT, Ha GH, Nguyen HLT, Do HN, et al. Depression and  
3 Quality of Life among Patients Living with HIV/AIDS in the Era of Universal Treatment Access in  
4 Vietnam. *Int J Environ Res Public Health*. 2018;15(12).
- 5 48. Seid S, Abdu O, Mitiku M, Tamirat KS. Prevalence of depression and associated factors  
6 among HIV/AIDS patients attending antiretroviral therapy clinic at Dessie referral hospital, South  
7 Wollo, Ethiopia. *Int J Ment Health Syst*. 2020;14:55.
- 8 49. Hankebo M, Fikru C, Lemma L, Aregago G. Depression and Associated Factors among  
9 People Living with Human Immunodeficiency Virus Attending Antiretroviral Therapy in Public  
10 Health Facilities, Hosanna Town, Southern Ethiopia. *Depress Res Treat*. 2023;2023:7665247.
- 11 50. Prochaska JJ. Smoking and mental illness—breaking the link. *New England Journal of  
12 Medicine*. 2011;365(3):196-8.
- 13 51. Leventhal AM, Zvolensky MJ. Anxiety, depression, and cigarette smoking: A  
14 transdiagnostic vulnerability framework to understanding emotion–smoking comorbidity.  
15 *Psychological bulletin*. 2015;141(1):176.
- 16 52. Fluharty M, Taylor AE, Grabski M, Munafo MR. The Association of Cigarette Smoking  
17 With Depression and Anxiety: A Systematic Review. *Nicotine Tob Res*. 2017;19(1):3-13.
- 18 53. Rubin LF, Haaga DA, Pearson JL, Gunthert KC. Depression as a moderator of the  
19 prospective relationship between mood and smoking. *Health Psychology*. 2020;39(2):99.
- 20 54. Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley N, Aveyard P. Change in  
21 mental health after smoking cessation: systematic review and meta-analysis. *Bmj*. 2014;348.
- 22 55. Kessler RC. Epidemiology of women and depression. *J Affect Disord*. 2003;74(1):5-13.
- 23 56. Waldron EM, Burnett-Zeigler I, Wee V, Ng YW, Koenig LJ, Pederson AB, et al. Mental  
24 Health in Women Living With HIV: The Unique and Unmet Needs. *J Int Assoc Provid AIDS  
25 Care*. 2021;20:2325958220985665.
- 26 57. Carmo Filho A, Fakoury MK, Eyer-Silva Wde A, Neves-Motta R, Kalil RS, Ferry FR.  
27 Factors associated with a diagnosis of major depression among HIV-infected elderly patients.  
28 *Rev Soc Bras Med Trop*. 2013;46(3):352-4.
- 29 58. Chibanda D, Cowan F, Gibson L, Weiss HA, Lund C. Prevalence and correlates of  
30 probable common mental disorders in a population with high prevalence of HIV in Zimbabwe.  
31 *BMC Psychiatry*. 2016;16:55.
- 32 59. Accortt EE, Freeman MP, Allen JJ. Women and major depressive disorder: clinical  
33 perspectives on causal pathways. *J Womens Health (Larchmt)*. 2008;17(10):1583-90.
- 34 60. Noble RE. Depression in women. *Metabolism*. 2005;54(5 Suppl 1):49-52.
- 35 61. Bhatia MS, Munjal S. Prevalence of Depression in People Living with HIV/AIDS  
36 Undergoing ART and Factors Associated with it. *J Clin Diagn Res*. 2014;8(10):WC01-4.
- 37 62. Lichtenstein B, Laska MK, Clair JM. Chronic sorrow in the HIV-positive patient: issues of  
38 race, gender, and social support. *AIDS Patient Care STDS*. 2002;16(1):27-38.
- 39 63. Badru OA, Babalola OE. Significant Others and Not Family or Friend Support Mediate  
40 Between Stigma and Discrimination Among People Living With HIV in Lagos State, Nigeria: A  
41 Cross-sectional Study. *Journal of the Association of Nurses in AIDS Care*. 2023;34(1):96-104.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# Reporting checklist for cross sectional study.

Based on the STROBE cross sectional guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cross sectional reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

			Page Number
<b>Title and abstract</b>			
Title	<a href="#">#1a</a>	Indicate the study's design with a commonly used term in the title or the abstract	1
Abstract	<a href="#">#1b</a>	Provide in the abstract an informative and balanced summary of what was done and what was found	1
<b>Introduction</b>			
Background / rationale	<a href="#">#2</a>	Explain the scientific background and rationale for the investigation being reported	2
Objectives	<a href="#">#3</a>	State specific objectives, including any prespecified hypotheses	2
<b>Methods</b>			
Study design	<a href="#">#4</a>	Present key elements of study design early in the paper	2
Setting	<a href="#">#5</a>	Describe the setting, locations, and relevant dates, including periods of	2



recruitment, exposure, follow-up, and data collection

1			
2			
3	Eligibility criteria	<a href="#">#6a</a>	Give the eligibility criteria, and the sources and methods of selection of participants. 2
4			
5			
6		<a href="#">#7</a>	Clearly define all outcomes, exposures, predictors, potential 3
7			confounders, and effect modifiers. Give diagnostic criteria, if applicable
8			
9			
10	Data sources /	<a href="#">#8</a>	For each variable of interest give sources of data and details of methods 3
11	measurement		of assessment (measurement). Describe comparability of assessment
12			methods if there is more than one group. Give information separately
13			for for exposed and unexposed groups if applicable.
14			
15			
16			
17	Bias	<a href="#">#9</a>	Describe any efforts to address potential sources of bias 3
18			
19	Study size	<a href="#">#10</a>	Explain how the study size was arrived at 2
20			
21	Quantitative	<a href="#">#11</a>	Explain how quantitative variables were handled in the analyses. If 3
22	variables		applicable, describe which groupings were chosen, and why
23			
24			
25	Statistical	<a href="#">#12a</a>	Describe all statistical methods, including those used to control for 3
26	methods		confounding
27			
28			
29	Statistical	<a href="#">#12b</a>	Describe any methods used to examine subgroups and interactions 3
30	methods		
31			
32			
33	Statistical	<a href="#">#12c</a>	Explain how missing data were addressed 3
34	methods		
35			
36			
37	Statistical	<a href="#">#12d</a>	If applicable, describe analytical methods taking account of sampling 3
38	methods		strategy
39			
40			
41	Statistical	<a href="#">#12e</a>	Describe any sensitivity analyses 3
42	methods		
43			
44			
45	<b>Results</b>		
46			
47	Participants	<a href="#">#13a</a>	Report numbers of individuals at each stage of study—eg numbers 4
48			potentially eligible, examined for eligibility, confirmed eligible,
49			included in the study, completing follow-up, and analysed. Give
50			information separately for for exposed and unexposed groups if
51			applicable.
52			
53			
54			
55	Participants	<a href="#">#13b</a>	Give reasons for non-participation at each stage 4
56			
57	Participants	<a href="#">#13c</a>	Consider use of a flow diagram 4
58			
59			
60			

1	Descriptive data	<a href="#">#14a</a>	Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders. Give information separately for exposed and unexposed groups if applicable.	4
2				
3				
4				
5				
6	Descriptive data	<a href="#">#14b</a>	Indicate number of participants with missing data for each variable of interest	4
7				
8				
9				
10	Outcome data	<a href="#">#15</a>	Report numbers of outcome events or summary measures. Give information separately for exposed and unexposed groups if applicable.	5
11				
12				
13				
14	Main results	<a href="#">#16a</a>	Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	4-7
15				
16				
17				
18				
19	Main results	<a href="#">#16b</a>	Report category boundaries when continuous variables were categorized	4-7
20				
21	Main results	<a href="#">#16c</a>	If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	4-7
22				
23				
24				
25	Other analyses	<a href="#">#17</a>	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	4-7
26				
27				
28				
29	<b>Discussion</b>			
30				
31	Key results	<a href="#">#18</a>	Summarise key results with reference to study objectives	8
32				
33				
34	Limitations	<a href="#">#19</a>	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.	8
35				
36				
37				
38				
39	Interpretation	<a href="#">#20</a>	Give a cautious overall interpretation considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.	8
40				
41				
42				
43				
44	Generalisability	<a href="#">#21</a>	Discuss the generalisability (external validity) of the study results	8
45				
46				
47	<b>Other</b>			
48	<b>Information</b>			
49				
50				
51	Funding	<a href="#">#22</a>	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	8
52				
53				
54				
55				

The STROBE checklist is distributed under the terms of the Creative Commons Attribution License CC-BY.

This checklist was completed on 23. June 2023 using <https://www.goodreports.org/>, a tool made by the

[EQUATOR Network](#) in collaboration with [Penelope.ai](#)

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

# BMJ Open

## Depression and associated factors among HIV-positive smokers receiving care at HIV outpatient clinics in Vietnam: a cross-sectional analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-077015.R2
Article Type:	Original research
Date Submitted by the Author:	26-Jan-2024
Complete List of Authors:	Nguyen, Nam; Institute of Social and Medical Studies Nguyen, Trang; Institute of Social and Medical Studies Vu, Giap; Bach Mai Hospital Truong, Nga; Institute of Social and Medical Studies Pham, Yen; Institute of Social and Medical Studies Guevara Alvarez, Gloria; New York University Armstrong-Hough, Mari ; New York University R Shelley, Donna; New York University
<b>Primary Subject Heading</b>:	Mental health
Secondary Subject Heading:	HIV/AIDS, Smoking and tobacco
Keywords:	Depression & mood disorders < PSYCHIATRY, HIV & AIDS < INFECTIOUS DISEASES, MENTAL HEALTH, PUBLIC HEALTH

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

## Depression and associated factors among HIV-positive smokers receiving care at HIV outpatient clinics in Vietnam: a cross-sectional analysis

Nam Truong Nguyen<sup>1</sup>, Trang Nguyen<sup>1</sup>, Giap Van Vu<sup>3</sup>, Nga Truong<sup>1</sup>, Yen Pham<sup>1</sup>, Gloria Guevara Alvarez<sup>2</sup>, Mari Armstrong-Hough<sup>2</sup>, Donna Shelley<sup>2</sup>

<sup>1</sup>Institute of Social and Medical Studies, Ha Noi, Vietnam

<sup>2</sup>School of Global Public Health, New York University, New York, NY, USA

<sup>3</sup>Bach Mai Hospital, Ha Noi, Vietnam

### Corresponding author

Nam Truong Nguyen

[ntnam@isms.org.vn](mailto:ntnam@isms.org.vn)

### ABSTRACT

#### Objectives

To assess the prevalence of depressive symptoms and associated factors among people living with HIV (PLWH) who were current cigarette smokers and receiving treatment at HIV outpatient clinics (OPCs) in Vietnam.

#### Design

A cross-sectional survey of smokers living with HIV.

#### Setting

The study was carried out in 13 HIV outpatient clinics located in Ha Noi, Vietnam.

#### Participants

The study included 527 people living with HIV aged 18 and above who were smokers and were receiving treatment at HIV outpatient clinics.

#### Outcome measures

The study used the Center for Epidemiology Scale for Depression (CES-D 8) to assess depressive symptoms. The associations between depressive symptoms, tobacco dependence, and other characteristics were explored using Bivariate and Poisson regression analyses.

#### Results

The prevalence of depressive symptoms among smokers living with HIV was 38.3%. HIV-positive smokers who were female (PR=1.51, 95% CI 1.02-2.22), unmarried (PR = 2.06, 95% CI 1.54-2.76), had a higher level of tobacco dependence (PR =1.06, 95% CI 1.01-1.11), and reported their health as fair or poor (PR =1.66, 95% CI 1.22-2.26) were more likely to have depression symptoms compared with HIV-positive smokers who were male, married, had a lower level of tobacco dependence, and self-reported their health as good, very good, or excellent.

#### Conclusion

1 The prevalence of depressive symptoms among smokers receiving HIV care at HIV outpatient  
2 clinics was high. Both depression and tobacco use screening and treatment should be included as  
3 part of ongoing care treatment plans at HIV outpatient clinics.

4 **Keywords:** Depression; depressive symptoms; tobacco use; HIV; people living with HIV;  
5 Vietnam; low-and middle-income country.  
6

### 7 **Strengths and limitations of this study**

- 9 • The study used the CES-D 8, a validated scale to screen depressive symptoms, and was  
10 conducted with a large sample of smokers living with HIV and receiving treatment at HIV  
11 outpatient clinics.
- 12 • Using the CES-D 8, which is a screening tool rather than a diagnostic instrument, this study  
13 could only assess the prevalence of depressive symptoms among PLWH instead of the  
14 prevalence of diagnosed depression.
- 15 • The study employed Poisson regression to estimate Prevalence Ratios, a more robust  
16 approach than logistic regression for analyzing cross-sectional studies with binary  
17 outcomes.
- 18 • The cross-sectional design did not allow for conclusions about the direction of the  
19 associations between depression and other factors.
- 20 • The study sample, which PLWH who were receiving treatment at HIV outpatient clinics,  
21 may not represent the larger population of PLWH in Vietnam.  
22  
23  
24

## 25 **INTRODUCTION**

26  
27 HIV infection remains a significant public health issue, with over 38 million people living with  
28 HIV (PLWH) globally [1]. With increased access to antiretroviral medication, HIV infection has  
29 become a manageable chronic health condition with a lifespan comparable to that of the general  
30 population [2, 3]. However, the growing burden of non-communicable diseases (NCDs) threatens  
31 gains in life expectancy among PLWH [4]. This is in part due to high rates of tobacco use in this  
32 population, particularly in LMIC countries like Vietnam, where smoking prevalence among male  
33 PLWH is over 50% [4, 5]. PLWH who use tobacco are at an increased risk of HIV and non-HIV-  
34 related chronic diseases that include cancer and cardiovascular diseases compared to PLWH who  
35 do not smoke [6].  
36  
37

38 PLWH experience other risk factors for poor health that include higher rates of depression  
39 compared with the general population [7-9]. Prevalence estimates for depression among PLWH  
40 range widely from 25.6% to 56.7% [6, 10-15]. Studies conducted in Vietnam show a similarly  
41 high prevalence of depression among PLWH, ranging from 18.7% to 44% [16-21].  
42  
43

44 Depression is common among smokers, particularly among smokers living with HIV [22, 23]. The  
45 high co-occurrence of smoking and depression in this population is a significant public health  
46 concern. Depression may contribute to lower smoking cessation rates, negatively impacts  
47 adherence to ART, and is associated with faster progression of the disease and a higher prevalence  
48 of other health risk behaviors, including alcohol abuse and drug use and poorer health outcomes  
49 [22, 24-29].  
50  
51

52 Despite the deleterious effects of the co-occurrence of depression and tobacco use on health  
53 outcomes among PLWH, there is a lack of data on the correlates of depression in this population.  
54 To begin to fill this gap in research, we conducted a cross-sectional analysis of factors associated  
55 with depressive symptoms among PLWH who smoked and were receiving treatment in HIV  
56 outpatient clinics in Ha Noi, Vietnam.  
57

## METHODS

### Study design

We analyzed data from baseline surveys conducted with 527 patients living with HIV who were enrolled in a randomized controlled trial (RCT) that compared the effectiveness of three smoking cessation interventions among PLWH who received care from 13 HIV outpatient clinics in Ha Noi, Vietnam. The surveys were conducted between 12/2022 and 6/2023. Participants were screened for tobacco use at the time of registration for a routine visit. Participants were eligible to enroll if they were 18 or older, active patients at the OPCs, current cigarette-only or dual users (water pipes and cigarettes), had a mobile phone, and lived in Ha Noi. Our analysis revealed no significant differences in gender, age, and smoking status between patients who declined to participate and those who enrolled in the study.

The survey was administered in person using a structured questionnaire in Vietnamese. All participants provided written informed consent. The institutional review boards of the Institute of Social Medical Studies (Decision 08/HDDD-ISMS) and the New York University School of Medicine (ID i19-01783) approved this research.

### Measures

#### Dependent variable

The study used the 8-item Center for Epidemiology Scale for Depression (CES-D 8) to assess depressive symptoms[30]. The CES-D 8 was previously validated in Vietnam[31]. In this study, Cronbach's alpha was 0.76, demonstrating a high level of internal consistency of the CES-D 8.

The survey asked respondents how often they experienced certain feelings in the past week. These include feeling depressed, feeling that everything they did was an effort, having restless sleep, feeling happy, feeling lonely, enjoying life, feeling sad, and having difficulty getting going. Responses were coded as 0=Rarely or none of the time (less than one day); 1= Some or a little of the time (1-2 days); 2= Occasionally or a moderate amount of time (3-4 days); 3= Most or all of the time (5-7 days). Scores can range from 0 to 24. A score of  $\geq 9$  indicates the presence of depressive symptoms. [32].

#### Independent variables

Health status was measured using a single question: "Would you say your health in general is excellent, very good, good, fair, or poor?" where 1 = Poor, 2= Fair, 3 = Good, 4 = Very Good, and 5 = Excellent [33].

Social support was assessed using the Multidimensional Scale of Perceived Social Support Scale (MPSS)[34], which aggregates three types of social support: significant other, family, and friends. Respondents were asked to rate 12 social support statements on a scale of 1 to 4, where 1 indicated "Strongly disagree" and 4 indicated "Strongly agree". The mean scores for each of the three social support categories were calculated.

Tobacco dependence was assessed using the Fagerstrom Test for Nicotine Dependence, which consists of six items that evaluate the quantity of cigarette consumption, the compulsion to use, and dependence[35]. The measured levels of tobacco dependence ranged from 'Very low dependence' with a score of 0-2 to 'Very high dependence' with a score of 8-10.

Alcohol use was assessed using the Alcohol Use Disorder Identification Test–Consumption (AUDIT–C)[36]. The AUDIT–C scale ranges from 0 to 12. Hazardous drinking was defined as a score of  $\geq 4$  for men and  $\geq 3$  for women [37].

Drug use was defined as the use of substances for psychotropic rather than medical purposes. The assessment of drug use was based on two questions that asked if respondents had ever used, and if they used in the past three months, any of the following substances: Opium, Cocaine, Heroin, Amphetamine/Methamphetamine, Marijuana, Ecstasy, MDMA, and Ketamine.

HIV characteristics include the number of years a person has lived with HIV and the duration of ART use. Having a chronic disease was assessed using one question that asked if the respondent has ever been diagnosed with any of the following chronic diseases: high blood pressure, diabetes, cancer, and lung disease. Sociodemographic variables include sex, age, marital status, educational status, household income, occupation, and living arrangements (e.g., living with children).

### Data analysis

The data were analyzed using Stata (version 14.0). Descriptive statistics were used to summarize the characteristics of PLWH and the prevalence of depressive symptoms. Bivariate tests were conducted with a significance level of 0.05. Categorical variables were assessed via chi-square tests, while continuous variables were assessed using t-tests. Multivariable analysis was performed using Poisson regression[38] to evaluate the associations between depression and other patient characteristics. Prevalence ratios (PR) were reported along with 95% confidence intervals. Independent variables that had a p-value  $< 0.2$  in the bivariate analyses were included in the logistic regression model [39]. P values  $< 0.05$  were considered statistically significant.

### Patient and public involvement

No patients or members of the public were involved in the design, conduct, reporting, and dissemination of the study.

## RESULTS

### Socio-demographic characteristics of the participants

A total of 527 PLWH were included in the study, of which 95.8% were male and 4.2% were female. This low prevalence of female smokers was consistent with national data demonstrating that less than 2% of women in Vietnam smoke cigarettes [40]. The average age of PLWH was 44.3 ( $\pm 7.0$ ). In terms of marital status and living arrangements, 53.9% of participants were married, while 46.1% were single, separated, divorced, or widowed, and 70.6% lived with spouses, partners, and children. Regarding education, employment, and income, 45.7% of participants had not completed high school education, 63.4% worked in small businesses, trading, services, or freelance, and 59.6% had an annual household income from 100-300 VND million (Table 1).

The mean duration of HIV diagnosis and ART treatment was 12.5 years ( $\pm 6.4$ ) and 10.1 years ( $\pm 6.5$ ).

In terms of health behavior, 48.6% were cigarette-only smokers, while 51.4% were dual users, meaning they smoked both cigarettes and water pipes. Moreover, 38.7% had a high or very high level of tobacco dependence, 55% had hazardous drinking habits, 62% reported having ever used drugs, and 18.6% had used drugs in the last three months.

Regarding health status, 71.7% reported very poor or poor health status, and 21.8% had at least one chronic disease.



## Prevalence and associated factors of depressive symptoms

The prevalence of depressive symptoms, as measured by a CED-8 score of 9 or higher, was 38.3% (Table 1).

Table 1 shows the results of bivariate analyses that examined the correlation between depressive symptoms and other patient characteristics. The prevalence of depressive symptoms was higher among PLWH who were female, unmarried, worked in small business, trading, services, and freelance, lived alone, reported fair or poor health status, had higher tobacco dependence levels, used drugs in the past three months, and reported lower levels of social support. In comparison, those who were male, married, worked in the private sector or other, lived with a spouse, partner, children, or with others, reported good, very good, or excellent health status, had lower levels of tobacco dependence, never used drugs, and had higher social support had a lower prevalence of depressive symptoms.

Table 2 presents results from multivariate analyses indicating significant associations between depressive symptoms and gender, marital status, level of tobacco dependence, and self-reported health status.

The probability of having depressive symptoms was significantly higher among females (PR=1.51, 95% CI 1.02-2.22), unmarried patients (PR = 2.06, 95% CI 1.54-2.76), patients with higher levels of tobacco dependence (PR =1.06, 95% CI 1.01-1.11), and those with fair or poor health status (PR =1.66, 95% CI 1.22-2.26), compared with patients who were males, married, had a lower level of tobacco dependence, and reported good, very good, or excellent health status.

**Table 1: PLWH's characteristics and bivariate analysis of factors associated with depressive symptoms**

Characteristics	Total		Depressive symptoms				P value
	n	% /Mean ±SD	No		Yes		
			n	% /Mean±SD	n	% /Mean±SD	
<b>Gender</b>							
Female	22	4.2	9	40.9	13	59.1	0.041
Male	505	95.8	316	62.6	189	37.4	
<b>Age (mean)</b>	527	44.3±7.0	325	44.6±7.0	202	43.8±6.9	0.174
<b>Marital status</b>							
Single/ Never married/Separated/Divorced	243	46.1	107	44.0	136	56.0	<0.001
Married	284	53.9	218	76.8	66	23.2	
<b>Education</b>							
Less than high school	241	45.7	151	62.7	90	37.3	0.473
High school	193	36.6	113	58.6	80	41.4	
Vocational training/ College/University and above	93	17.7	61	65.6	32	34.4	
<b>Occupation</b>							
Private sector	108	20.5	71	65.7	37	34.3	0.038
Small business/ Trading/Services/Freelance	334	63.4	193	57.8	141	42.2	
Others	85	16.1	61	71.8	24	28.2	

Characteristics	Total		Depressive symptoms				P value
	n	% / Mean ±SD	No		Yes		
			n	% / Mean ±SD	n	% / Mean ±SD	
<b>Household income in the past 12 months</b>							
50,000,000 - < 100,000,000	153	29.0	88	57.5	65	42.5	0.425
100,000,000 - < 300,000,000	314	59.6	200	63.7	114	36.3	
300,000,000 and over 500,000,000	57	10.8	36	63.2	21	36.8	
<b>Living arrangements</b>							
Live alone	44	8.3	20	45.5	24	54.5	<0.001
Live with spouse/partner/children /grandchildren	372	70.6	257	69.1	115	30.9	
Live with others	111	21.1	48	43.2	63	56.8	
<b>Duration of diagnosed with HIV</b>	527	12.5±6.4	325	12.4±6.5	202	12.8±6.3	0.449
<b>Duration of ART</b>	527	10.1±6.5	325	10.0±5.5	202	10.3±7.9	0.643
<b>Have depressive symptoms</b>							
No	325	61.7					
Yes	202	38.3					
<b>Have a chronic disease</b>							
No	412	78.2	262	63.6	150	36.4	0.086
Yes	115	21.8	63	54.8	52	45.2	
<b>Current health status</b>							
Good/Very good/Excellent	149	28.3	113	75.8	36	24.2	<0.001
Fair/Poor	378	71.7	212	56.1	166	43.9	
<b>Type of smoker</b>							
Cigarettes only	256	48.6	158	61.7	98	38.3	0.982
Dual user	271	51.4	167	61.6	104	38.4	
<b>Tobacco dependence level</b>							
Very low/Low	248	47.1	174	70.2	74	29.8	0.001
Medium	75	14.2	41	54.7	34	45.3	
High/Very high	204	38.7	110	53.9	94	46.1	
Tobacco dependence (score)	527	4.4±2.5	325	4.0±2.6	202	5.0±2.3	<0.001
<b>Hazardous drinking</b>							
No	237	45.0	136	57.4	101	42.6	0.067
Yes	290	55.0	189	65.2	101	34.8	
<b>Drug use</b>							
Never	102	19.4	73	71.6	29	28.4	0.026
Ever	327	62.1	200	61.2	127	38.8	
In the last 3 months	98	18.6	52	53.1	46	46.9	
<b>Social support</b>							
Family support score	527	3.2±0.5	325	3.2±0.5	202	3.1±0.5	0.100

Characteristics	Total		Depressive symptoms				P value
	n	% /Mean ±SD	No		Yes		
			n	% /Mean±SD	n	% /Mean±SD	
Friend support score	527	2.9±0.6	325	2.9±0.5	202	2.8±0.5	0.211
Other support score	527	3.2±0.5	325	3.2±0.5	202	3.1±0.5	0.041
<b>Total social support score (min-max: 1.33-4.33)</b>	527	3.3±0.4	325	3.4±0.4	202	3.3±0.4	0.038

**Table 2: Multivariate analysis of factors associated with depressive symptoms among PLWH using Poisson regression**

Characteristics	PR (95% CI)	P value
<b>Gender</b>		
Male (ref.)	-	
Female	1.51 (1.02-2.22)	<b>0.039</b>
<b>Age (mean)</b>	1.00 (0.99-1.02)	0.914
<b>Marital status</b>		
Married (ref.)	-	
Single/ Never married/Separated/Divorced	2.06 (1.54-2.76)	<b>&lt;0.001</b>
<b>Occupation</b>		
Private sector (ref.)	-	
Small business/ Trading/Services/Freelance	1.08 (0.82-1.42)	0.583
Others	0.75 (0.50-1.12)	0.166
<b>Living arrangements</b>		
Live alone (ref.)	-	
Live with spouse/partner/children /grandchildren	0.96 (0.68-1.35)	0.819
Live with others	1.04 (0.75-1.44)	0.815
<b>Have a chronic disease</b>		
No (ref.)	-	
Yes	1.16 (0.94-1.45)	0.161
<b>Current health status</b>		
Good/Very good/Excellent (ref.)	-	
Fair/Poor	1.66 (1.22-2.26)	<b>0.001</b>
<b>Tobacco dependence (score)</b>	1.06 (1.01-1.11)	<b>0.014</b>
<b>Hazardous drinking</b>		
No (ref.)	-	

	Yes	0.86 (0.71-1.05)	0.150
<b>Drug use</b>			
	Never (ref.)	-	
	Ever	1.08 (0.78-1.49)	0.647
	In the last 3 months	1.08 (0.76-1.53)	0.686
<b>Total social support score</b>		0.91 (0.72-1.15)	0.411

## DISCUSSION

This study found a high prevalence of depressive symptoms (38.3%) among PLWH who smoked and were receiving HIV care in OPCs in Vietnam. This prevalence is 16 times higher than the previously reported prevalence of depressive symptoms in the general Vietnamese population (2.5%) [41]. Our findings are consistent with prior studies showing a high prevalence of depressive symptoms among PLWH compared to the general population [42, 43].

Depression is the most common mental health problem among PLWH [44, 45]. The high prevalence of depressive symptoms in this population is attributed to HIV-associated biological factors and psychosocial factors, which include occupational disability, financial difficulties, stigma, discrimination, isolation, and debilitation [46][47-49].

We found that smokers living with HIV with higher levels of tobacco dependence were more likely to report higher levels of depressive symptoms compared with smokers living with HIV who had a lower level of tobacco dependence. The literature on the direction of this relationship is inconsistent [50-52]. PLWH with depression may use nicotine to elevate their mood. On the other hand, smoking may lead to depression through changes in the brain's susceptibility to environmental stress [52, 53]. Concern among clinicians about exacerbating depression symptoms has hindered the treatment of tobacco use. However, there is growing evidence that suggests that smoking cessation has beneficial effects on mental health symptoms [54]. It is critically important to develop and implement models of care that combine mental health and tobacco cessation for this population.

The prevalence of depressive symptoms among female smokers living with HIV was higher than that among male smokers living with HIV. This finding is consistent with previous studies that depression is more common among women with HIV compared to the general population, women without HIV [55], and men with HIV[56-58]. Women are at a higher risk of depression due to a variety of factors, including genetic vulnerability, reproductive hormones, internalization coping strategies, gender-specific roles, and life stress [59, 60]. In addition, women living with HIV experience higher levels of perceived stress and HIV stigma [56]. These added stressors may consequently contribute to an increased risk of depression among women with HIV.

Consistent with other studies on PLWH [8, 61], this study found a higher prevalence of depressive symptoms among unmarried smokers living with HIV. Having a diagnosis of HIV, a disease that is associated with high levels of perceived stigma, may prevent PLWH from entering and maintaining a marital relationship. HIV-associated stigma may lead to social isolation and loneliness for those without meaningful relationships and social ties [62]. Increased loneliness and isolation, along with a lack of psychological and tangible support, may increase the risk of depression among PLWH who are not married. Social support, particularly from significant others,

1 can reduce perceived stigma and consequently decrease the risk of depression and is also  
2 associated with improved quality of life, reduced symptoms of depression, and better adherence to  
3 ART [63]. More research is needed to identify effective methods for enhancing social support in  
4 the context of HIV care.

5 Finally, this study is consistent with previous studies [19, 21] that found an association between  
6 self-reported poor health and depressive symptoms. The direction of this relationship is also not  
7 clear and may, in part, be related to concurrent tobacco use. However, the finding further highlights  
8 that optimizing quality of life and health outcomes requires addressing both mental health and  
9 tobacco use as part of routine HIV care.

10  
11 There are some limitations to this analysis. First, the cross-sectional design does not allow for  
12 conclusions about the direction of the associations. For example, poorer health may contribute to  
13 depressive symptoms and vice versa. Second, participants were drawn from a sample of PLWH  
14 who were receiving treatment at HIV OPCs. Therefore, this sample of PLWH may not represent  
15 the larger population of PLWH in Vietnam. However, most PLWH in Vietnam receive ART at  
16 OPCs. Lastly, the CES-D 8 is a screening tool rather than a diagnostic instrument. As a result, this  
17 study was only able to assess the prevalence of depressive symptoms among PLWH rather than  
18 the prevalence of diagnosed depression.  
19  
20

## 21 CONCLUSIONS

22  
23 Findings from this study and prior literature indicate that there is a high prevalence of co-occurring  
24 depression and tobacco use among PLWH, which negatively impacts disease progression and  
25 health outcomes in this population. Thus, it is imperative to provide resources and training to  
26 integrate screening and effective treatment for both tobacco use and depression into routine care  
27 in HIV treatment settings. Further enhancing social support through additional services and  
28 programs may facilitate engagement in tobacco use treatment and improve health outcomes among  
29 PLWH who smoke [53].  
30  
31  
32  
33

34  
35 **Contributors:** Designed the study: DS, NN. Developed data collection tools: DS, NN, TN, GG,  
36 MA, GV. Collected data: NT, YP. Analyzed data and interpreted results: TN, NT, YP. Wrote the  
37 initial draft: NN, DS. Contributed to subsequent drafts: DS, GG, MA, TN, GV. All authors  
38 reviewed and approved the final manuscript.  
39

40  
41 **Funding:** This work was supported by the National Cancer Institute, US National Institutes of  
42 Health (grant number R01CA240481).  
43

44 **Competing interests:** None declared.

45 **Patient consent for publication:** Not required.

46  
47 **Ethics approval:** The institutional review boards of the Institute of Social Medical Studies  
48 (Decision 08/HDDD-ISMS) and the New York University School of Medicine (ID i19-01783).  
49

50 **Data availability statement:** available upon reasonable request.  
51  
52  
53  
54  
55  
56  
57

## REFERENCES

1. World Health Organization. Factsheet. HIV and AIDS 2023 [Available from: <https://www.who.int/news-room/fact-sheets/detail/hiv-aids>].
2. Mdege ND, Shah S, Ayo-Yusuf OA, Hakim J, Siddiqi K. Tobacco use among people living with HIV: analysis of data from Demographic and Health Surveys from 28 low-income and middle-income countries. *The Lancet Global Health*. 2017;5(6):e578-e92.
3. Mills EJ, Bakanda C, Birungi J, Chan K, Ford N, Cooper CL, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. *Ann Intern Med*. 2011;155(4):209-16.
4. Parascandola M, Neta G, Bloch M, Gopal S. Colliding epidemics: research gaps and implementation science opportunities for tobacco use and HIV/AIDS in low-and middle-income countries. *Journal of Smoking Cessation*. 2022;2022.
5. Nguyen NPT, Tran BX, Hwang LY, Markham CM, Swartz MD, Phan HTT, et al. Prevalence of cigarette smoking and associated factors in a large sample of HIV-positive patients receiving antiretroviral therapy in Vietnam. *PloS one*. 2015;10(2):e0118185.
6. Abadiga M. Depression and its associated factors among HIV/AIDS patients attending ART clinics at Gimbi General hospital, West Ethiopia, 2018. *BMC Res Notes*. 2019;12(1):527.
7. Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. *American journal of psychiatry*. 2001;158(5):725-30.
8. Mekonen T, Belete H, Fekadu W. Depressive symptoms among people with HIV/AIDS in Northwest Ethiopia: comparative study. *BMJ Open*. 2021;11(7):e048931.
9. Rabkin JG. HIV and depression: 2008 review and update. *Current Hiv/aids Reports*. 2008;5:163-71.
10. Ayano G, Tsegay L, Solomon M. Food insecurity and the risk of depression in people living with HIV/AIDS: a systematic review and meta-analysis. *AIDS Research and Therapy*. 2020;17(1):1-11.
11. Gritz ER, Vidrine DJ, Lazev AB, Amick BC, Arduino RC. Smoking behavior in a low-income multiethnic HIV/AIDS population. *Nicotine & Tobacco Research*. 2004;6(1):71-7.
12. Brown T, Morgan K. Psychological distress and substance abuse in Jamaican youths living with HIV/AIDS. *West Indian Medical Journal*. 2013;62(4).
13. Zhang C, Li X, Liu Y, Qiao S, Zhou Y, Shen Z, et al. Substance Use and Psychosocial Status among People Living with HIV/AIDS Who Encountered HIV Stigma in China: Stratified Analyses by Socio-Economic Status. *PLOS ONE*. 2016;11(11):e0165624.
14. Duko B, Geja E, Zewude M, Mekonen S. Prevalence and associated factors of depression among patients with HIV/AIDS in Hawassa, Ethiopia, cross-sectional study. *Ann Gen Psychiatry*. 2018;17:45.
15. Olanrewaju Gt IBA. Prevalence and Correlates of Depressive Disorders among People Living with HIV/AIDS, in North Central Nigeria. *Journal of AIDS & Clinical Research*. 2013;04(01).
16. Esposito CA, Steel Z, Gioi TM, Huyen TT, Tarantola D. The prevalence of depression among men living with HIV infection in Vietnam. *Am J Public Health*. 2009;99 Suppl 2(Suppl 2):S439-44.
17. Matsumoto S, Yamaoka K, Takahashi K, Tanuma J, Mizushima D, Do CD, et al. Social Support as a Key Protective Factor against Depression in HIV-Infected Patients: Report from large HIV clinics in Hanoi, Vietnam. *Sci Rep*. 2017;7(1):15489.
18. Huynh VN, To KG, Do DV, To QG, Nguyen MT. Changes in depressive symptoms and correlates in HIV+ people at An Hoa Clinic in Ho Chi Minh City, Vietnam. *BMC Psychiatry*. 2017;17(1):35.
19. Thai TT, Jones MK, Harris LM, Heard RC, Hills NK, Lindan CP. Symptoms of Depression in People Living with HIV in Ho Chi Minh City, Vietnam: Prevalence and Associated Factors. *AIDS Behav*. 2018;22(Suppl 1):76-84.

20. Green K, Tuan T, Hoang TV, Trang NN, Ha NT, Hung ND. Integrating palliative care into HIV outpatient clinical settings: preliminary findings from an intervention study in Vietnam. *J Pain Symptom Manage*. 2010;40(1):31-4.
21. Levintow SN, Pence BW, Ha TV, Minh NL, Sripaipan T, Latkin CA, et al. Prevalence and predictors of depressive symptoms among HIV-positive men who inject drugs in Vietnam. *PLoS One*. 2018;13(1):e0191548.
22. Junaid K, Afzal S, Daood M, Siddiqui M. Substance Abuse and Mental Health Issues Among HIV/AIDS Patients. *Journal of the College of Physicians and Surgeons--Pakistan: JCPSP*. 2023;33(3):325-34.
23. Teixeira LSL, Ceccato M, Carvalho WDS, Costa JO, Bonolo PF, Mendes JC, et al. Prevalence of smoking and associated factors in people living with HIV undergoing treatment. *Rev Saude Publica*. 2020;54:108.
24. Deborah Kacanek DLJ, Donna Spiegelman, Christine Wanke, Rita Isaac, and Ira B. Wilson. Incident Depression Symptoms Are Associated With Poorer HAART Adherence: A Longitudinal Analysis From the Nutrition for Healthy Living Study. *Acquir Immune Defic Syndr*. 2010;53.
25. Do HM, Dunne MP, Kato M, Pham CV, Nguyen KV. Factors associated with suboptimal adherence to antiretroviral therapy in Viet Nam: a cross-sectional study using audio computer-assisted self-interview (ACASI). *BMC Infect Dis*. 2013;13:154.
26. Meade CS, Sikkema KJ. HIV risk behavior among adults with severe mental illness: a systematic review. *Clinical psychology review*. 2005;25(4):433-57.
27. Ryan K, Forehand R, Solomon S, Miller C. Depressive symptoms as a link between barriers to care and sexual risk behavior of HIV-infected individuals living in non-urban areas. *AIDS care*. 2008;20(3):331-6.
28. Antelman G, Kaaya S, Wei R, Mbwambo J, Msamanga GI, Fawzi WW, et al. Depressive symptoms increase risk of HIV disease progression and mortality among women in Tanzania. *J Acquir Immune Defic Syndr*. 2007;44(4):470-7.
29. Kingori C, Haile ZT, Ngatia P. Depression symptoms, social support and overall health among HIV-positive individuals in Kenya. *Int J STD AIDS*. 2015;26(3):165-72.
30. Radloff LS. The CES-D scale: A self-report depression scale for research in the general population. *Applied psychological measurement*. 1977;1(3):385-401.
31. Moulis L, Le SM, Hai VV, Huong DT, Minh KP, Oanh KTH, et al. Gender, homelessness, hospitalization and methamphetamine use fuel depression among people who inject drugs: implications for innovative prevention and care strategies. *Frontiers in Psychiatry*. 2023;14.
32. Briggs R, Carey D, O'Halloran AM, Kenny RA, Kennelly SP. Validation of the 8-item Centre for Epidemiological Studies Depression Scale in a cohort of community-dwelling older people: data from The Irish Longitudinal Study on Ageing (TILDA). *Eur Geriatr Med*. 2018;9(1):121-6.
33. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Quality of life research*. 2011;20(10):1727-36.
34. Zimet GD, Dahlem NW, Zimet SG, Farley GK. The multidimensional scale of perceived social support. *Journal of personality assessment*. 1988;52(1):30-41.
35. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerström test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. *British journal of addiction*. 1991;86(9):1119-27.
36. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. *Archives of internal medicine*. 1998;158(16):1789-95.
37. Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief screen for alcohol misuse in primary care. *Alcohol Clin Exp Res*. 2007;31(7):1208-17.
38. Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. *BMC Med Res Methodol*. 2003;3:21.

39. Vittinghoff E, Shiboski S, Glidden D, McCulloch C. *Regression Methods in Biostatistics: Linear, Logistic, Survival and Repeated Measures Models*. New York: Springer; 2011.
40. Van Minh H, Giang KB, Ngoc NB, Hai PT, Huyen DT, Khue LN, et al. Prevalence of tobacco smoking in Vietnam: findings from the Global Adult Tobacco Survey 2015. *Int J Public Health*. 2017;62(Suppl 1):121-9.
41. World Health Organization. Factsheet. Mental Health in Vietnam [Available from: <https://www.who.int/vietnam/health-topics/mental-health>].
42. Jeffrey A. Ciesla MAJER, Ph.D. *Meta-Analysis of the Relationship Between HIV Infection and Risk for Depressive Disorders*. *Am J Psychiatry*. 2001.
43. Rabkin JG. *HIV and Depression: 2008 Review and Update*. 2008.
44. Adams C, Zacharia S, Masters L, Coffey C, Catalan P. Mental health problems in people living with HIV: changes in the last two decades: the London experience 1990-2014. *AIDS Care*. 2016;28 Suppl 1(sup1):56-9.
45. Gaynes BN, Pence BW, Eron JJ, Miller WC. Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. *Psychosom Med*. 2008;70(4):505-11.
46. Arseniou S, Arvaniti A, Samakouri M. HIV infection and depression. *Psychiatry Clin Neurosci*. 2014;68(2):96-109.
47. Tran BX, Dang AK, Truong NT, Ha GH, Nguyen HLT, Do HN, et al. Depression and Quality of Life among Patients Living with HIV/AIDS in the Era of Universal Treatment Access in Vietnam. *Int J Environ Res Public Health*. 2018;15(12).
48. Seid S, Abdu O, Mitiku M, Tamirat KS. Prevalence of depression and associated factors among HIV/AIDS patients attending antiretroviral therapy clinic at Dessie referral hospital, South Wollo, Ethiopia. *Int J Ment Health Syst*. 2020;14:55.
49. Hankebo M, Fikru C, Lemma L, Aregaw G. Depression and Associated Factors among People Living with Human Immunodeficiency Virus Attending Antiretroviral Therapy in Public Health Facilities, Hosanna Town, Southern Ethiopia. *Depress Res Treat*. 2023;2023:7665247.
50. Prochaska JJ. Smoking and mental illness—breaking the link. *New England Journal of Medicine*. 2011;365(3):196-8.
51. Leventhal AM, Zvolensky MJ. Anxiety, depression, and cigarette smoking: A transdiagnostic vulnerability framework to understanding emotion–smoking comorbidity. *Psychological bulletin*. 2015;141(1):176.
52. Fluharty M, Taylor AE, Grabski M, Munafò MR. The Association of Cigarette Smoking With Depression and Anxiety: A Systematic Review. *Nicotine Tob Res*. 2017;19(1):3-13.
53. Rubin LF, Haaga DA, Pearson JL, Gunthert KC. Depression as a moderator of the prospective relationship between mood and smoking. *Health Psychology*. 2020;39(2):99.
54. Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley N, Aveyard P. Change in mental health after smoking cessation: systematic review and meta-analysis. *Bmj*. 2014;348.
55. Kessler RC. Epidemiology of women and depression. *J Affect Disord*. 2003;74(1):5-13.
56. Waldron EM, Burnett-Zeigler I, Wee V, Ng YW, Koenig LJ, Pederson AB, et al. Mental Health in Women Living With HIV: The Unique and Unmet Needs. *J Int Assoc Provid AIDS Care*. 2021;20:2325958220985665.
57. Carmo Filho A, Fakoury MK, Eyer-Silva Wde A, Neves-Motta R, Kalil RS, Ferry FR. Factors associated with a diagnosis of major depression among HIV-infected elderly patients. *Rev Soc Bras Med Trop*. 2013;46(3):352-4.
58. Chibanda D, Cowan F, Gibson L, Weiss HA, Lund C. Prevalence and correlates of probable common mental disorders in a population with high prevalence of HIV in Zimbabwe. *BMC Psychiatry*. 2016;16:55.
59. Accortt EE, Freeman MP, Allen JJ. Women and major depressive disorder: clinical perspectives on causal pathways. *J Womens Health (Larchmt)*. 2008;17(10):1583-90.
60. Noble RE. Depression in women. *Metabolism*. 2005;54(5 Suppl 1):49-52.
61. Bhatia MS, Munjal S. Prevalence of Depression in People Living with HIV/AIDS Undergoing ART and Factors Associated with it. *J Clin Diagn Res*. 2014;8(10):WC01-4.



- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
62. Lichtenstein B, Laska MK, Clair JM. Chronic sorrow in the HIV-positive patient: issues of race, gender, and social support. *AIDS Patient Care STDS*. 2002;16(1):27-38.
63. Badru OA, Babalola OE. Significant Others and Not Family or Friend Support Mediate Between Stigma and Discrimination Among People Living With HIV in Lagos State, Nigeria: A Cross-sectional Study. *Journal of the Association of Nurses in AIDS Care*. 2023;34(1):96-104.

For peer review only

# Reporting checklist for cross sectional study.

Based on the STROBE cross sectional guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cross sectional reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

	Reporting Item	Page Number
<b>Title and abstract</b>		
Title	<a href="#">#1a</a> Indicate the study's design with a commonly used term in the title or the abstract	1
Abstract	<a href="#">#1b</a> Provide in the abstract an informative and balanced summary of what was done and what was found	1
<b>Introduction</b>		
Background / rationale	<a href="#">#2</a> Explain the scientific background and rationale for the investigation being reported	2
Objectives	<a href="#">#3</a> State specific objectives, including any prespecified hypotheses	2
<b>Methods</b>		
Study design	<a href="#">#4</a> Present key elements of study design early in the paper	2
Setting	<a href="#">#5</a> Describe the setting, locations, and relevant dates, including periods of	2

recruitment, exposure, follow-up, and data collection

1			
2			
3	Eligibility criteria	<a href="#">#6a</a>	Give the eligibility criteria, and the sources and methods of selection of participants. 2
4			
5			
6		<a href="#">#7</a>	Clearly define all outcomes, exposures, predictors, potential 3
7			confounders, and effect modifiers. Give diagnostic criteria, if applicable
8			
9			
10	Data sources /	<a href="#">#8</a>	For each variable of interest give sources of data and details of methods 3
11	measurement		of assessment (measurement). Describe comparability of assessment
12			methods if there is more than one group. Give information separately
13			for for exposed and unexposed groups if applicable.
14			
15			
16			
17	Bias	<a href="#">#9</a>	Describe any efforts to address potential sources of bias 3
18			
19	Study size	<a href="#">#10</a>	Explain how the study size was arrived at 2
20			
21	Quantitative	<a href="#">#11</a>	Explain how quantitative variables were handled in the analyses. If 3
22	variables		applicable, describe which groupings were chosen, and why
23			
24			
25	Statistical	<a href="#">#12a</a>	Describe all statistical methods, including those used to control for 3
26	methods		confounding
27			
28			
29	Statistical	<a href="#">#12b</a>	Describe any methods used to examine subgroups and interactions 3
30	methods		
31			
32			
33	Statistical	<a href="#">#12c</a>	Explain how missing data were addressed 3
34	methods		
35			
36			
37	Statistical	<a href="#">#12d</a>	If applicable, describe analytical methods taking account of sampling 3
38	methods		strategy
39			
40			
41	Statistical	<a href="#">#12e</a>	Describe any sensitivity analyses 3
42	methods		
43			
44			
45	<b>Results</b>		
46			
47	Participants	<a href="#">#13a</a>	Report numbers of individuals at each stage of study—eg numbers 4
48			potentially eligible, examined for eligibility, confirmed eligible,
49			included in the study, completing follow-up, and analysed. Give
50			information separately for for exposed and unexposed groups if
51			applicable.
52			
53			
54			
55	Participants	<a href="#">#13b</a>	Give reasons for non-participation at each stage 4
56			
57	Participants	<a href="#">#13c</a>	Consider use of a flow diagram 4
58			
59			
60			

1	Descriptive data	<a href="#">#14a</a>	Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders. Give information separately for exposed and unexposed groups if applicable.	4
2				
3				
4				
5				
6	Descriptive data	<a href="#">#14b</a>	Indicate number of participants with missing data for each variable of interest	4
7				
8				
9				
10	Outcome data	<a href="#">#15</a>	Report numbers of outcome events or summary measures. Give information separately for exposed and unexposed groups if applicable.	5
11				
12				
13				
14	Main results	<a href="#">#16a</a>	Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	4-7
15				
16				
17				
18				
19	Main results	<a href="#">#16b</a>	Report category boundaries when continuous variables were categorized	4-7
20				
21	Main results	<a href="#">#16c</a>	If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	4-7
22				
23				
24				
25	Other analyses	<a href="#">#17</a>	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	4-7
26				
27				
28				
29	<b>Discussion</b>			
30				
31	Key results	<a href="#">#18</a>	Summarise key results with reference to study objectives	8
32				
33				
34	Limitations	<a href="#">#19</a>	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.	8
35				
36				
37				
38				
39	Interpretation	<a href="#">#20</a>	Give a cautious overall interpretation considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.	8
40				
41				
42				
43				
44	Generalisability	<a href="#">#21</a>	Discuss the generalisability (external validity) of the study results	8
45				
46				
47	<b>Other</b>			
48	<b>Information</b>			
49				
50				
51	Funding	<a href="#">#22</a>	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	8
52				
53				
54				
55				

The STROBE checklist is distributed under the terms of the Creative Commons Attribution License CC-BY.

This checklist was completed on 23. June 2023 using <https://www.goodreports.org/>, a tool made by the

[EQUATOR Network](#) in collaboration with [Penelope.ai](#)

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>